

# Cancer Incidence and Mortality in New Jersey 1998 - 2002

Prepared by:  
Xiaoling Niu, MS  
Pamela Agovino, MPH  
Lisa M. Roche, MPH, PhD  
Toshi Abe, MSW, CTR  
Susan Van Loon, RN, CTR  
Betsy A. Kohler, MPH, CTR

James E. McGreevey  
Governor

Clifton R. Lacy, M.D.  
Commissioner

Eddy A. Bresnitz, MD, MS  
State Epidemiologist/ Senior Assistant Commissioner

New Jersey Department of Health and Senior Services  
Center for Cancer Initiatives

PO Box 369  
Trenton, NJ 08625-0369  
(609) 588-3500  
[www.state.nj.us/health](http://www.state.nj.us/health)

October 2004

## **ACKNOWLEDGMENTS**

The following staff of the New Jersey State Cancer Registry and the Surveillance Program of Cancer Epidemiology Services were involved in the collection, quality assurance and preparation of the data on incident cases of cancer in New Jersey:

Anne Marie Anepete, CTR	Harrine Katz, CTR
Pamela Beasley	Henry Lewis, MPH
Donna Brown	Helen Martin, CTR
Stasia S. Burger, MS, CTR	Ilsia Martin, MS
Emiliano Cornago	Kevin Masterson, CTR
Kathleen Diszler, RN, CTR	John Murphy, CTR
Thomas English, CTR	Lisa Paddock, MPH
Cynthia Evans, CTR	Maithili Patnaik, CTR
Erica Falaise	Theresa Pavlovcak, CTR
Lorraine Fernbach, CTR	Karen Pawlish, MS, Sc.D
Ruthann Filipowicz	Barbara Pingitor
Maria Halama, MD, CTR	Gladys Pyatt-Dickson, CTR
Marilyn Hansen, CTR	Karen Robinson-Frasier, CTR
Joan Hess, RN, CTR	Susan Sanna, CTR
Stephanie Hill, CTR	Antonio Savillo, MD, CTR
Margaret Hodnicki, RN, CTR	Suzanne Schwartz, MS, CTR
Yvette Humphries	Rekha Tharwani, MD
Nicole Jackson	Celia Troisi, CTR
Susan Jacobs	Helen Weiss, RN, CTR
Jamal Johnson	Michael Wellins
Linda Johnson, CTR	Homer Wilcox III
Catherine Karnicky, CTR	

We also acknowledge New Jersey hospitals, laboratories, physicians, dentists, and the states of Delaware, Florida, Maryland, New York, North Carolina, and Pennsylvania who reported cancer cases to the New Jersey State Cancer Registry.

## TABLE OF CONTENTS

Introduction.....	1
Technical Notes.....	2
Registry Over view .....	2
Data Sources.....	3
Data Quality .....	3
Improved Reporting .....	4
Description of Algorithm for Designating Hispanic Ethnicity.....	4
Exclusion of Unknown County.....	5
Incidence and Mortality Coding .....	6
Age-adjusted Rates and the Year 2000 Standard .....	6
Population Denominators for 2000.....	7
Calculation of Rates.....	7
Suppression of Rates and Counts Under Five .....	8
References.....	9

## TABLES

Table 1.	<b>Age-adjusted Incidence Rates, Males (all races combined)</b>
Table 2.	<b>Age-adjusted Incidence Rates, Females (all races combined)</b>
Table 3.	<b>Age-adjusted Incidence Rates, White Males</b>
Table 4.	<b>Age-adjusted Incidence Rates, White Females</b>
Table 5.	<b>Age-adjusted Incidence Rates, Black Males</b>
Table 6.	<b>Age-adjusted Incidence Rates, Black Females</b>
Table 7.	<b>Age-adjusted Incidence Rates, Hispanic Males and Females (combined years)</b>
Table 8.	<b>Comparative Incidence Rates, New Jersey and U.S., 1997-2001: Males</b>
Table 9.	<b>Comparative Incidence Rates, New Jersey and U.S., 1997-2001: Females</b>
Table 10.	<b>Age-adjusted Mortality Rates, Males (all races combined)</b>
Table 11.	<b>Age-adjusted Mortality Rates, Females (all races combined)</b>
Table 12.	<b>Age-adjusted Mortality Rates, White Males</b>
Table 13.	<b>Age-adjusted Mortality Rates, White Females</b>
Table 14.	<b>Age-adjusted Mortality Rates, Black Males</b>
Table 15.	<b>Age-adjusted Mortality Rates, Black Females</b>
Table 16.	<b>Age-adjusted Mortality Rates, Hispanic Males and Females (combined years)</b>
Table 17.	<b>Comparative Mortality Rates, New Jersey and U.S., 1997-2001: Males</b>
Table 18.	<b>Comparative Mortality Rates, New Jersey and U.S., 1997-2001: Females</b>
Table 19.	<b>Population Denominators</b>
Table 20.	<b>Age Distribution of Cancer Incidence</b>
Table 21.	<b>Median Age at Cancer Diagnosis</b>

## **INTRODUCTION**

The following tables present statewide, age-adjusted incidence rates and counts for all cancers diagnosed among New Jersey residents during the period 1998-2002, age-adjusted mortality rates and counts for the period 1998-2001 and comparisons of state and national rates for 1997-2001. The incidence data for 2002 should be considered preliminary.

The primary goal of this report is to provide 1998-2002 data to health planners, researchers and the public. Data are provided statewide for six population subgroups: white men, white women, black men, black women, Hispanic men and Hispanic women. Data are also provided by gender for all races combined.

For each year, the age-adjusted incidence and mortality rates per 100,000 population are shown for 66 categories of cancer and for all sites combined. For women, breast cancer *in situ* statistics are shown but not included in the totals for all sites combined. For both men and women, bladder cancer *in situ* cases are included with invasive urinary bladder, urinary system and all sites. Basal and squamous cell skin cancers are not collected and therefore not included in the data tables. These conventions are standard practice for publication of cancer rates in the United States.

## TECHNICAL NOTES

### Registry Overview

The objectives of the New Jersey State Cancer Registry (NJSCR) are to:

- \* monitor cancer trends in New Jersey
- \* promote scientific research
- \* respond to New Jersey residents about cancer concerns
- \* educate the public
- \* provide information for planning and evaluating cancer prevention and control activities and
- \* share and compare cancer data with other states and the nation.

The New Jersey State Cancer Registry is a population-based cancer incidence registry that serves the entire state of New Jersey, which has a population of over 8.4 million people. The NJSCR was established by legislation (NJSA 26:2-104 et. seq.) and includes all cases of cancer diagnosed in New Jersey residents since October 1, 1978. New Jersey regulations (NJAC 8:57A) require the reporting of all newly diagnosed cancer cases to the NJSCR within three months of hospital discharge or six months of diagnosis, whichever is sooner. Reports are filed by hospitals, diagnosing physicians, dentists, and independent clinical laboratories. Every hospital in New Jersey reports cancer cases electronically. In addition, reporting agreements are maintained with New York, Pennsylvania, Delaware, Florida, Maryland, and North Carolina so that New Jersey residents diagnosed with cancer outside the state can be identified. Legislation in 1996 strengthened the Registry by (1) requiring electronic reporting, (2) requiring abstracting by certified tumor registrars and (3) establishing penalties for late or incomplete reporting.

All primary invasive and *in situ* neoplasms are reportable to the NJSCR, except cervical cancer *in situ* diagnosed after 1994 and certain carcinomas of the skin. The information collected by the NJSCR includes basic patient identifiers, demographic characteristics of the patient, medical information on each cancer diagnosis (such as the anatomic site, histologic type and stage of disease), first course of treatment and vital status (alive or deceased) determined annually. For deceased cases, the underlying cause of death is also included. The primary site, behavior, grade, and histology of each cancer are coded according to the *International Classification of Diseases for Oncology (ICD-O)*, 2<sup>nd</sup> edition for cancers diagnosed through 2000 and the 3<sup>rd</sup> edition for cancers diagnosed after 2000. The NJSCR follows the data standards promulgated by the North American Association of Central Cancer Registries (NAACCR), including the use of the Surveillance, Epidemiology, and End Results (SEER) multiple primary rules. An individual may develop more than one cancer. Following the SEER multiple primary rules, patients could therefore be counted more than once if they were diagnosed with two or more primary cancers.

The NJSCR is a member of NAACCR, an organization that sets standards for cancer registries, facilitates data exchange, and publishes cancer data. The NJSCR has been a participant of the National Program of Cancer Registries (NPCR) sponsored by the Centers for Disease Control and Prevention (CDC) since it began in 1994 and is one of the National Cancer Institute's (NCI) SEER expansion registries.

## **Data Sources**

New Jersey cancer incidence data were taken from the August 2004 analytic file and tabulated using SEER\*Stat (<http://seer.cancer.gov/ScientificSystems/SEERStat/>), a statistical software package distributed by the NCI. New Jersey cancer mortality data were obtained through the NCI's Surveillance, Epidemiology and End Results (SEER) Program from the National Center for Health Statistics (NCHS) and also tabulated using SEER\*Stat. U.S. cancer incidence and mortality data were obtained from NAACCR's publication, *Cancer in North America 1997-2001*. At the time of this report, year 2002 mortality data were unavailable. The 1997-2001 population estimates were provided by the National Cancer Institute's SEER Program. Since the 2002 population data were not available at the time the 2002 incidence rates were calculated, 2001 population data were used for 2002.

Out-of-state residents and cases whose residence in NJ could not be confirmed (unknown county) are excluded from New Jersey rates and counts. Persons of unknown age and/or gender are also excluded. Race-specific information is not shown separately for persons who are races other than white or black (including unknown race), but these persons are included in the "all races" data.

## **Data Quality**

NAACCR has awarded the Gold Standard, the highest standard possible, to the NJSCR for the quality of the 1995 through 2001 data. The NJSCR has consistently achieved the highest level of certification for its data since the inception of this award. The criteria used to judge the quality of the data are completeness of cancer case ascertainment, completeness of certain information on the cancer cases, percent of death certificate only cases, percent of duplicate cases, passing an editing program, and timeliness.

Completeness of reporting was estimated by comparing New Jersey and U.S. incidence to mortality ratios for whites standardized for age, gender, and cancer site. The data used to generate these ratios were the cancer incidence rates for all SEER registries combined. Using these standard formulae, it is possible for the estimation of completeness to be greater than 100 percent. For 2002 data, the completeness of case reporting was estimated as 102.4 percent at the time this report was prepared.

While our estimates of completeness are very high, some cases of cancer among New Jersey residents who were diagnosed and/or treated in out-of-state facilities may not yet have been reported to the NJSCR by other state registries. This should be considered in interpreting the data for the more recent years. However, these relatively few cases will not significantly affect the cancer rates, or alter the overall trends presented in this report.

Other 2002 cancer incidence data quality indicators measured were as follows:

- Percent death-certificate-only cases: 2.3 percent
- Percent of unresolved duplicates: < 0.1 percent
- Percent of cases with unknown race: 1.6 percent
- Percent of cases with unknown county: .09 percent
- Number of cases with unknown age: 9
- Number of cases with unknown gender: 9

It should also be noted that minor fluctuations may be seen from previous incidence reports due to ongoing editing and review of the data. Compared to preliminary data for 2001 published in our last report, 2001 incidence rates for total cancer in this report increased by 2.3 percent for men and 1.1 percent for women. Similarly, the 2002 incidence rates presented here are expected to increase by the time all data are complete. For county level data you may visit the NJSCR's interactive cancer data mapping application, which will be available in the near future at:

<http://www.state.nj.us/health/cancer/phpp.htm>

### **Improved Reporting**

The NJSCR continues to work toward improving the quality and number of its reporting sources. Over the past year, significant improvements have been realized in this regard. For example some of these improvements have resulted in better reporting of leukemia and skin cancers such as melanoma, which may explain some of the increases seen in these cancers. One of the most significant improvements has been the implementation of electronic pathology laboratory reporting (E-path) from a national pathology laboratory and several hospital-based laboratories. The ultimate goal is to enable E-path laboratory reporting from every laboratory that serves New Jersey. E-path reporting is expected to improve the timeliness and completeness of cancer reporting, especially for non-hospitalized cases.

### **Description of Algorithm for Designating Hispanic Ethnicity**

In 2003, the NJSCR adopted the NAACCR Hispanic Identification Algorithm (NHIA) to assign Hispanic ethnicity to cases. This method uses data on birthplace, marital status, gender, race and surname match to the 1990 Hispanic surname list to augment the number of cases and decedents reported as Hispanic in the registry during the years 1994-2002.

Prior to the development of the NHIA, the NJSCR used a method to assign Hispanic ethnicity to cases that was adapted from algorithms developed by the Illinois State Cancer Registry (ISCR) and by the NJSCR. NHIA is closely related to these former algorithms, so there is high agreement between the cases previously determined to be Hispanic and those currently determined to be Hispanic.



As a result of using the NHIA, the NJSCR was able to increase the number of Hispanic cases by 22 percent for this time period, thereby correcting an under identification of Hispanics. For a more complete description of the NHIA and a copy of the NHIA SAS program visit the following link at the NAACCR website:

<http://www.naaccr.org/filesystem/pdf/Package%205%202005%20CFD.pdf>

Caution should be used when comparing the cancer incidence rates for Hispanics in this report with previous reports due to 1) modifications to the Hispanic algorithm resulting in a slight increase in the number of incident cases determined to be Hispanic; and, 2) improvements in health care facility practices to obtain accurate ethnicity categorization of patients resulting in additional cases being designated as Hispanic.

Caution should be used when comparing rates among Hispanics with the rates in the different race groups (e.g. black, white) because ethnicity and race are not mutually exclusive. In New Jersey, the majority (89 percent) of Hispanics identify themselves as white. The Hispanics who identify themselves as white are included in the white race category as well as the all races category.

Caution should also be used when comparing Hispanic mortality data to Hispanic incidence data in this report. Hispanic mortality data for this report were obtained from NCI's SEER Program and did not have the NHIA algorithm applied to them. In our detailed report, *Cancer Among Hispanics in New Jersey, 1990-1996*, our previous Hispanic algorithm was applied to mortality data from the New Jersey Center for Health Statistics, resulting in an increased mortality rate of 13 percent for men and 23 percent for women.

### **Exclusion of Unknown County**

In order to minimize the number of cases with an unknown county of residence, the NJSCR runs all addresses through a standardization and geocoding process. Cases are also followed back to physicians and hospitals to verify address data. For this report, cases where the county of residence is unknown have been excluded. This is a change from previous reports, in which cases with unknown county were included. This change was made so that NJSCR methods are in accordance with the standard procedures used by SEER. The effect of this change on the incidence rates is very small. The total number of cases with unknown county for the 5 years combined (1998-2002) is 223, which represents .09% of the total case population.

## **Incidence and Mortality Coding**

Beginning with the year 2001, the coding scheme for incident cancer cases changed from the *International Classification of Diseases for Oncology, 2<sup>nd</sup> edition (ICD-0-2)* to the *3<sup>rd</sup> edition (ICD-0-3)*. Several newly reportable cancers were added to the *ICD-0-3* manual and are presently being grouped under “Ill-Defined and Unspecified” sites. The addition of chronic myeloproliferative disorders and myelodysplastic syndromes are responsible for a marked increase in the “Ill-Defined and Unspecified” sites in 2001 and 2002 from previous years. The following SEER web link contains additional information on the transition from *ICD-0-2* to *ICD-0-3*:

[http://training.seer.cancer.gov/module\\_icdo3/downloadables/ICDO3%20abstract%20n%20article%20NEW%20PDF.pdf](http://training.seer.cancer.gov/module_icdo3/downloadables/ICDO3%20abstract%20n%20article%20NEW%20PDF.pdf)

Beginning with the year 1999, coding and classification for cause of death is in accordance with the *10<sup>th</sup> edition* of the World Health Organization's *International Classification of Diseases (ICD-10)*. From 1979-1998, cause of death coding is based on the *9<sup>th</sup> edition (ICD-9)*. Changes in classification detail, coding rules, and classification code numbers with this new version have caused some discontinuities in trends for cancer deaths. Although these discontinuities vary, research has found that using ICD-10 assigns approximately 0.7 percent more deaths to the category of cancer, which may slightly increase some site-specific mortality rates for 1999 and later.

## **Age-adjusted Rates and the Year 2000 Standard**

The U.S. Department of Health and Human Services requires that health data be age-adjusted using the U.S. Year 2000 population as a standard, beginning with the 1999 reporting year. Age-adjustment to the year 2000 population as the standard was first used in one of our earlier reports, *Cancer Incidence and Mortality in New Jersey 1996-2000*, issued in December 2002. Prior to the release of 1999 data, various federal and state agencies calculated disease rates using different U.S. population standards, including the 1940 and 1970 standard populations. Our report *Cancer Incidence and Mortality in New Jersey, 1995-1999*, issued in September 2001, used the former 1970 population standard for all five years and also illustrated the effect on 1999 incidence rates of changing the population standard from 1970 to 2000.

Calculations using the 2000 standard population do not indicate a change in cancer incidence or occurrence—only a different representation of the rates of reported cancer. Using the 2000 population as the standard produces standardized cancer rates that appear to be about 20 percent higher than previously reported.

## **Population Denominators for 2000**

The population data used in this report were downloaded from the SEER's website <http://seer.cancer.gov/popdata/>. The population estimates now incorporate bridged single-race estimates for July 1, 2000 and 2001, which are derived from the original multiple race categories in the 2000 Census (as specified in the *1997 Office of Management and Budget Standards* for the collection of data on race and ethnicity). For agencies such as NCI and NCHS to continue reporting long-term trends in disease rates for single-race groups, a method is needed to "bridge" these multi-race classifications into a single-race category. Such a method was developed by NCHS using information collected as part of their National Health Interview Surveys. In collaboration with NCHS, the Census Bureau produced a set of year 2000 population estimates that assigned everyone to one race group only. The resulting 2000 estimates were then used to produce an improved set of 1991-2001 population estimates. The bridged single-race estimates and a more in-depth description of the methodology used to develop them appear on the National Center for Health Statistics (NCHS) web site located at the following link:

<http://www.cdc.gov/nchs/about/major/dvs/popbridge/popbridge.htm>

With the inclusion of the year 2000 population data, we must take into account the new way in which the U.S. Bureau of the Census collected population data. With the 2000 Census, individuals were given the opportunity to categorize themselves as more than one race. For the first time, individuals could "mark [X] one or more races to indicate what this person considers himself/herself to be". Because of this change, 2000 population estimates for "White only" and "Black only" in earlier cancer incidence and mortality reports, are 4-6 percent lower than the 1999 populations for "White only" and "Black only" in New Jersey. Therefore, the NJSCR cautions the reader that when comparing the age-adjusted incidence rates for 2000, 2001 and 2002 by race to earlier years, it is not clear if an apparent rate change is actual or an artifact of the new way in which the U.S. Bureau of the Census collected race data for 2000.

Furthermore, 2000 population estimates used to calculate rates for the years 1991 through 1999 for previous reports have been found to differ from the actual 2000 census counts, especially the specific race and ethnicity estimates. Therefore, the 1991-1999 intercensal population estimates were revised by the Census Bureau by distributing the difference between the original post-1990 census estimates of the 2000 population and the actual April 1, 2000 census. The new population estimates affected primarily smaller populations such as race or Hispanic ethnicity subgroups.

## **Calculation of Rates**

A cancer incidence rate is defined as the number of new cases of cancer detected during a specified time period in a specified population. Cancer rates are most commonly expressed as cases per 100,000 population. Cancer occurs at different rates in different age groups, and population subgroups defined by gender and race have different age distributions. Therefore, before a valid comparison can be made between rates, it is necessary to standardize the rates to the age distribution of a standard population. In this report, the 2000 U.S. population standard was used. Records that were missing gender, age, or race were not included in the rates

presented in this report. Since the number of records so affected was very small, the rates were virtually unaffected by the non-inclusion of these records.

The first step in the age-standardization procedure is to determine the age-specific rates. For each age group for a given time interval (within each race-gender group, for the entire state), the following formula is applied:

$$r_a = \frac{n_a}{t \times P_a}$$

where:

- $r_a$  = the age-specific rate for age group a,
- $n_a$  = the number of events (cancer diagnoses) in the age group during the time interval,
- $t$  = the length of the time interval (in years), and
- $P_a$  = average size of the population in the age group during the time interval (mid-year population or average of mid-year population sizes).

In order to determine the age-adjusted rate, a weighted average of the age-specific rates is calculated, using the age distribution of the standard population to derive the age-specific weighting factors (Rothman, 1986). This is the technique of direct standardization, which uses the following formula:

$$R = \frac{\sum_{a=1}^n r_a \times Std. P_a}{\sum_{a=1}^n Std. P_a}$$

where:

- $R$  = the age-adjusted rate
- $r_a$  = the age-specific rate for age group a, and
- $Std.P_a$  = the size of the standard population in each age group a.

While age standardization facilitates the comparison of rates among different populations, there can be important age-specific differences in disease occurrence, which are not apparent in comparisons of the age-adjusted rates (Breslow and Day, 1987).

Analogous definitions and calculations apply for cancer mortality rates.

### **Suppression of Rates and Counts Under Five**

It should also be noted that the annual rates for relatively uncommon cancers tend to fluctuate substantially from year to year because of small numbers of cases, particularly in minority populations. Rates generated from small numbers should be interpreted with caution. For this report, rates were suppressed where counts were less than 5 as a way to ensure a greater level of statistical reliability.

## References

Breslow NE and Day NE. *Statistical Methods in Cancer Research. Volume II – The Design and Analysis of Cohort Studies*. New York: Oxford University Press. 1987.

Chiang CL. "Standard error of the age-adjusted death rate". In Vital Statistics Special Reports, Volume 47, Number 9. USDHEW, PHS, Washington, D.C. U.S. Government Printing Office, 1961.

Fritz A., Percy C. *Implementing ICD-O-3: Impact of the New Edition* SEER Program, National Cancer Institute.  
[URL. [http://training.seer.cancer.gov/module\\_icdo3/downloadables/ICDO3%20abstract%20n%20article%20NEW%20PDF.pdf](http://training.seer.cancer.gov/module_icdo3/downloadables/ICDO3%20abstract%20n%20article%20NEW%20PDF.pdf) ], accessed September 24, 2004]

Martin, Rose Marie. "Age Standardization of Death Rates in New Jersey: Implications of a Change in the Standard Population". Topics in Health Statistics. Center for Health Statistics. 2000;01-02.

McLaughlin C., Hotes JL, Wu XC et al (eds). *Cancer in North America, 1997-2001 Volumes 1-3*. North American Association of Central Cancer Registries, April 2004. [URL. [http://www.naaccr.org/index.asp?Col\\_SectionKey=11&Col\\_ContentID=50](http://www.naaccr.org/index.asp?Col_SectionKey=11&Col_ContentID=50), assessed September 24, 2004]

National Center for Health Statistics. *U.S. Census Population with Bridged Race Categories*, September 2004. [URL. <http://www.cdc.gov/nchs/about/major/dvs/popbridge/popbridge.htm>, accessed September 27, 2004]

North American Association of Central Cancer Registries "Best Practice Guideline for Hispanic Identification, NAACCR Approach to Hispanic Identification", Springfield, Illinois: U.S. [URL. <http://www.naaccr.org/filesystem/pdf/Package%205%202005%20CFD.pdf>, accessed September 24, 2004]

Rothman K. *Modern Epidemiology*. U.S.A. Little, Brown, and Company. 1986.

Surveillance, Epidemiology, and End Results (SEER) Program ([www.seer.cancer.gov](http://www.seer.cancer.gov)) *Population Estimates Used in NCI's SEER\*Stat Software*, January, 2004. [URL <http://seer.cancer.gov/popdata/methods.pdf>, accessed September 24, 2004]

Surveillance, Epidemiology, and End Results (SEER) Program ([www.seer.cancer.gov](http://www.seer.cancer.gov)) SEER\*Stat Database: Mortality - All COD, Public-Use With State, Total U.S. (1969-2001), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2004. Underlying mortality data provided by NCHS ([www.cdc.gov/nchs](http://www.cdc.gov/nchs)). [URL. <http://seer.cancer.gov/popdata/> ], accessed September 24, 2004]

Surveillance, Epidemiology, and End Results (SEER) Program ([www.seer.cancer.gov](http://www.seer.cancer.gov)) SEER\*Stat Database: Populations - Total U.S. (1969-2001), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2004. [URL. <http://seer.cancer.gov/popdata/> ], accessed September, 24, 2004]

United States Census Bureau. "*Major Differences in Subject-Matter Content Between 1990 and 2000 Census Questionnaires-Race*", October 2003.

[URL. <http://www.census.gov/population/www/cen2000/90vs00.html>., accessed September 24, 2004]

Weinstein R, Lee YS and Klotz J. *Cancer Among Hispanics in New Jersey 1990-1996*. New Jersey Department of Health and Senior Services, June 2000.

[URL. <http://www.state.nj.us/health/cancer/hispanic/>., accessed September 24, 2004]

**Table 1. Age-adjusted Incidence Rates, Males All Races Combined**

Cancer Site	Total Cases	Rates				
		1998	1999	2000	2001	2002 Prelim.
<b>All Sites</b>	117,984	634.1	622.5	625.0	642.8	642.4
<b>Oral Cavity and Pharynx</b>	2,905	16.0	14.5	15.4	14.5	14.5
Lip	137	0.9	0.6	0.7	0.7	0.9
Tongue	837	4.8	3.9	4.1	4.4	4.1
Salivary Gland	313	1.9	1.4	1.8	1.7	1.6
Floor of Mouth	207	1.2	1.2	0.8	1.0	1.1
Gum and Other Mouth	367	2.1	1.8	2.0	1.8	1.9
Nasopharynx	190	0.9	1.1	1.1	0.8	0.9
Tonsil	376	2.0	1.6	2.1	1.8	1.9
Oropharynx	109	0.4	0.6	0.8	0.3	0.6
Hypopharynx	276	1.3	1.5	1.6	1.6	1.3
<b>Digestive System</b>	23,461	135.4	131.1	126.2	125.2	124.1
Esophagus	1,649	9.6	8.8	9.0	8.5	8.2
Stomach	2,587	15.3	15.2	12.6	13.6	14.3
Small Intestine	410	2.1	2.3	2.2	2.2	2.1
Colon and Rectum	13,768	80.4	78.6	75.5	72.5	72.1
Colon excluding Rectum	9,568	56.8	55.5	52.6	50.8	50.4
Rectum and Rectosigmoid Junction	4,200	23.6	23.0	22.9	21.7	21.7
Anus, Anal Canal and Anorectum	196	1.1	1.2	0.7	1.0	1.2
Liver and Intrahepatic Bile Duct	1,591	8.0	7.1	8.9	9.5	8.7
Liver	1,431	6.9	6.2	7.9	8.7	8.0
Intrahepatic Bile Duct	160	1.1	0.9	1.0	0.9	0.7
Gallbladder	185	1.3	0.8	1.0	1.1	0.9
Pancreas	2,514	13.9	14.1	13.6	14.0	13.3
<b>Respiratory System</b>	18,554	109.4	99.4	100.5	96.4	95.8
Larynx	1,525	8.6	7.6	8.2	8.4	7.2
Lung and Bronchus	16,301	96.6	88.2	88.2	83.9	84.9
<b>Bones and Joints</b>	244	1.2	1.1	1.1	1.5	1.2
<b>Soft Tissue (Including Heart)</b>	746	4.0	4.0	3.7	3.9	3.9
<b>Skin (Excluding Basal and Squamous)</b>	4,714	22.9	22.2	22.6	26.1	30.0
Melanoma of the Skin	4,157	19.8	19.7	19.6	23.0	26.9

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

**Table 1 (continued). Age-adjusted Incidence Rates, Males All Races Combined**

Cancer Site	Total Cases	Rates				
		1998	1999	2000	2001	2002 Prelim.
<b>Breast</b>	260	1.4	1.6	1.2	1.4	1.3
<b>Male Genital System</b>	39,169	192.7	200.9	208.6	217.8	222.1
Prostate	37,746	186.0	194.3	201.8	210.6	214.7
Testis	1,198	5.3	5.6	5.5	6.0	6.1
Penis	177	1.1	0.7	1.1	0.9	1.1
<b>Urinary System</b>	12,145	66.2	67.2	66.1	67.1	64.5
Urinary Bladder (Including in situ)	8,226	45.2	46.8	45.7	46.5	43.7
Kidney and Renal Pelvis	3,623	19.1	18.5	18.6	19.3	19.4
Ureter	192	1.3	1.1	1.1	1.0	0.8
<b>Eye and Orbit</b>	185	1.2	0.6	1.2	0.9	0.9
<b>Brain and Other Nervous System</b>	1,609	8.8	8.0	8.7	7.7	7.9
Brain	1,497	8.2	7.4	8.1	7.1	7.5
<b>Endocrine System</b>	1,154	4.8	5.2	6.2	5.6	6.8
Thyroid	957	3.9	4.2	5.2	4.5	5.8
<b>Lymphomas</b>	5,616	31.0	29.3	28.0	30.7	28.3
Hodgkin Lymphoma	724	3.7	3.8	3.3	3.8	3.3
Non-Hodgkin Lymphoma	4,892	27.3	25.6	24.7	26.9	25.0
<b>Myelomas</b>	1,342	7.5	6.7	7.5	7.3	7.4
<b>Leukemias</b>	3,003	16.5	16.7	15.0	17.0	15.5
Lymphocytic Leukemia	1,442	8.1	8.0	7.0	8.4	7.1
Acute Lymphocytic Leukemia	349	2.1	1.9	1.2	1.7	1.9
Chronic Lymphocytic Leukemia	955	5.4	5.4	5.0	5.8	4.7
Myeloid and Monocytic Leukemia	1,339	7.1	7.2	6.6	7.7	7.2
Acute Myeloid Leukemia	885	4.3	4.8	4.1	5.4	5.0
Acute Monocytic Leukemia	51	0.3	0.4	0.3	0.1	0.2
Chronic Myeloid Leukemia	368	2.2	1.8	2.0	1.9	1.8
Other Leukemia	222	1.3	1.6	1.3	1.0	1.2
<b>Ill-Defined &amp; Unspecified Sites</b>	2,877	15.0	14.0	13.0	*19.7	*18.3

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

\* Increase in Ill-Defined & Unspecified rates is due to newly reportable ill-defined cases beginning in 2001.



**Table 2. Age-adjusted Incidence Rates, Females All Races Combined**

Cancer Site	Total Cases	Rates				
		1998	1999	2000	2001	2002 Prelim.
<b>All Sites</b>	111,744	463.1	451.3	452.7	456.6	447.1
<b>Oral Cavity and Pharynx</b>	1,523	6.2	7.0	5.8	6.0	5.9
Lip	70	0.3	0.3	0.2	0.3	0.2
Tongue	387	1.5	1.8	1.5	1.7	1.5
Salivary Gland	253	1.2	0.9	1.0	1.1	1.0
Floor of Mouth	104	0.6	0.4	0.4	0.3	0.5
Gum and Other Mouth	323	1.3	1.7	1.2	1.2	1.1
Nasopharynx	81	0.3	0.4	0.3	0.3	0.5
Tonsil	121	0.4	0.8	0.5	0.5	0.4
Oropharynx	59	0.2	0.3	0.3	0.2	0.2
Hypopharynx	75	0.3	0.3	0.3	0.3	0.3
<b>Digestive System</b>	21,602	87.1	82.8	83.3	82.8	82.0
Esophagus	614	2.3	2.4	2.4	2.5	2.4
Stomach	1,649	7.6	6.5	6.2	5.8	5.6
Small Intestine	363	1.3	1.5	1.3	1.5	1.7
Colon and Rectum	13,927	56.8	52.7	53.3	53.7	52.5
Colon excluding Rectum	10,523	42.5	39.4	39.8	41.1	39.2
Rectum and Rectosigmoid Junction	3,404	14.4	13.3	13.5	12.6	13.2
Anus, Anal Canal and Anorectum	346	1.2	1.3	1.5	1.6	1.4
Liver and Intrahepatic Bile Duct	738	2.8	2.8	3.1	3.1	2.7
Liver	550	1.8	2.1	2.2	2.4	2.3
Intrahepatic Bile Duct	188	1.0	0.7	0.8	0.6	0.5
Gallbladder	428	1.8	1.7	1.6	1.7	1.4
Pancreas	2,861	11.1	11.2	11.7	10.1	10.9
<b>Respiratory System</b>	14,623	59.8	58.5	57.8	58.3	57.9
Larynx	406	2.2	1.7	1.5	1.5	1.5
Lung and Bronchus	13,920	56.4	55.5	55.1	55.7	55.3
<b>Bones and Joints</b>	213	1.3	0.9	1.0	0.9	0.7
<b>Soft Tissue (Including Heart)</b>	671	2.7	2.4	3.1	2.9	3.0
<b>Skin (Excluding Basal and Squamous)</b>	3,486	13.1	12.5	13.7	16.0	17.6
Melanoma of the Skin	3,197	11.7	11.5	12.6	14.9	16.3
<b>Breast (Invasive)</b>	32,806	140.4	139.2	137.6	134.6	130.3
in situ (not included in All Sites)	7,907	32.3	34.0	33.7	33.7	35.7

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

**Table 2 (continued). Age-adjusted Incidence Rates, Females All Races Combined**

Cancer Site	Total Cases	Rates				
		1998	1999	2000	2001	2002 Prelim.
<b>Female Genital System</b>	14,480	63.3	61.6	60.4	60.0	56.4
Cervix Uteri	2,328	10.8	10.5	9.9	10.0	9.1
Corpus and Uterus, NOS	7,011	29.8	29.6	28.3	29.3	28.2
Corpus Uteri	6,744	28.3	28.5	27.3	28.4	27.3
Uterus, NOS	267	1.5	1.1	1.0	1.0	0.9
Ovary	4,182	18.9	18.1	18.1	16.6	15.3
Vagina	157	0.5	0.6	0.8	0.8	0.5
Vulva	630	2.6	2.1	2.5	2.4	2.7
<b>Urinary System</b>	5,566	21.2	21.6	21.5	22.6	23.1
Urinary Bladder (Including in situ)	3,100	11.6	11.2	12.8	12.4	12.1
Kidney and Renal Pelvis	2,311	9.1	9.7	8.2	9.6	10.2
Ureter	115	0.4	0.5	0.3	0.4	0.6
<b>Eye and Orbit</b>	168	0.9	0.5	0.7	0.8	0.4
<b>Brain and Other Nervous System</b>	1,384	6.3	6.5	6.1	5.5	5.1
Brain	1,256	5.5	6.0	5.6	5.0	4.6
<b>Endocrine System</b>	3,085	10.2	11.4	14.9	15.5	16.2
Thyroid	2,928	9.4	10.9	14.2	14.6	15.6
<b>Lymphomas</b>	5,204	22.9	21.0	21.4	21.0	20.3
Hodgkin Lymphoma	678	3.1	3.0	3.1	3.2	3.1
Non-Hodgkin Lymphoma	4,526	19.7	18.0	18.3	17.8	17.2
<b>Myelomas</b>	1,312	5.5	4.7	5.4	5.5	4.6
<b>Leukemias</b>	2,343	9.5	9.5	9.7	9.4	9.5
Lymphocytic Leukemia	1,039	3.8	4.3	4.4	4.2	4.7
Acute Lymphocytic Leukemia	271	1.3	1.2	1.5	1.1	1.3
Chronic Lymphocytic Leukemia	710	2.3	2.8	2.6	2.8	3.1
Myeloid and Monocytic Leukemia	1,093	4.6	4.4	4.5	4.7	4.1
Acute Myeloid Leukemia	751	3.0	3.0	3.1	3.4	2.8
Acute Monocytic Leukemia	44	0.2	0.1	0.2	-	0.2
Chronic Myeloid Leukemia	259	1.1	1.1	1.1	1.1	0.9
Other Leukemia	211	1.1	0.9	0.8	0.5	0.8
<b>Ill-Defined &amp; Unspecified Sites</b>	3,278	12.6	10.9	10.3	*14.6	*14.0

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

\* Increase in Ill-Defined & Unspecified rates is due to newly reportable ill-defined cases beginning in 2001.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 3. Age-adjusted Incidence Rates, White Males**

Cancer Site	Total Cases	Rates				
		1998	1999	2000	2001	2002 Prelim.
<b>All Sites</b>	101,028	630.1	620.7	626.5	636.2	630.9
<b>Oral Cavity and Pharynx</b>	2,334	14.5	14.2	14.6	13.9	14.0
Lip	132	1.0	0.7	0.8	0.8	0.9
Tongue	685	4.5	3.7	4.0	4.4	4.0
Salivary Gland	269	1.8	1.5	1.9	1.7	1.6
Floor of Mouth	163	1.0	1.2	0.9	0.7	1.1
Gum and Other Mouth	300	2.0	1.8	1.9	1.8	1.8
Nasopharynx	125	0.6	1.0	0.8	0.7	0.6
Tonsil	297	1.7	1.5	2.1	1.7	1.8
Oropharynx	86	0.3	0.6	0.8	0.3	0.6
Hypopharynx	206	0.9	1.4	1.2	1.5	1.2
<b>Digestive System</b>	19,954	132.6	129.4	125.5	122.4	119.9
Esophagus	1,356	8.9	8.6	8.6	7.7	8.1
Stomach	2,092	14.4	14.6	11.8	12.3	13.3
Small Intestine	330	1.9	2.1	2.1	2.1	2.0
Colon and Rectum	11,986	80.8	79.1	76.5	72.3	70.9
Colon excluding Rectum	8,313	57.0	55.3	53.0	50.4	49.4
Rectum and Rectosigmoid Junction	3,673	23.8	23.8	23.5	21.9	21.4
Anus, Anal Canal and Anorectum	154	1.0	1.1	0.6	1.0	1.1
Liver and Intrahepatic Bile Duct	1,228	7.2	6.6	8.4	8.6	7.6
Liver	1,087	6.2	5.7	7.3	7.7	6.9
Intrahepatic Bile Duct	141	1.0	0.9	1.1	0.9	0.7
Gallbladder	158	1.3	0.8	1.0	1.2	0.8
Pancreas	2,174	13.7	13.4	13.6	14.4	13.3
<b>Respiratory System</b>	15,900	107.8	98.0	99.6	95.7	94.3
Larynx	1,246	8.5	7.2	7.7	7.9	6.9
Lung and Bronchus	13,988	94.8	86.9	87.3	83.7	83.5
<b>Bones and Joints</b>	202	1.2	1.2	1.1	1.6	1.2
<b>Soft Tissue (Including Heart)</b>	645	4.3	4.0	3.8	4.0	3.9
<b>Skin (Excluding Basal and Squamous)</b>	4,528	25.6	25.1	25.8	29.5	33.6
Melanoma of the Skin	4,081	22.7	22.8	22.7	26.5	30.6

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

**Table 3 (continued). Age-adjusted Incidence Rates, White Males**

Cancer Site	Total Cases	Rates				
		1998	1999	2000	2001	2002 Prelim.
<b>Breast</b>	220	1.5	1.6	1.3	1.2	1.3
<b>Male Genital System</b>	32,532	187.9	194.4	203.0	207.5	209.2
Prostate	31,221	180.2	186.7	195.1	199.3	200.5
Testis	1,116	6.3	6.7	6.6	7.1	7.3
Penis	151	1.1	0.6	1.0	0.9	1.2
<b>Urinary System</b>	11,175	70.0	71.3	69.7	71.3	67.9
Urinary Bladder (Including in situ)	7,734	48.5	50.7	48.7	49.7	46.8
Kidney and Renal Pelvis	3,167	19.5	18.7	19.0	20.1	19.7
Ureter	184	1.4	1.2	1.2	1.1	0.8
<b>Eye and Orbit</b>	166	1.2	0.7	1.3	1.0	0.9
<b>Brain and Other Nervous System</b>	1,403	9.0	8.4	9.4	8.0	8.2
Brain	1,313	8.4	7.7	8.8	7.4	8.0
<b>Endocrine System</b>	999	5.3	5.5	6.4	5.7	7.2
Thyroid	833	4.3	4.5	5.5	4.5	6.1
<b>Lymphomas</b>	4,833	31.2	29.5	29.3	31.2	29.2
Hodgkin Lymphoma	610	3.8	3.8	3.4	4.2	3.7
Non-Hodgkin Lymphoma	4,223	27.4	25.6	26.0	27.0	25.5
<b>Myelomas</b>	1,060	6.7	6.2	7.0	6.6	6.9
<b>Leukemias</b>	2,618	16.8	17.3	15.7	17.5	15.4
Lymphocytic Leukemia	1,270	8.5	8.4	7.6	8.8	6.8
Acute Lymphocytic Leukemia	289	2.2	1.9	1.4	1.8	1.9
Chronic Lymphocytic Leukemia	857	5.7	5.8	5.3	6.0	4.4
Myeloid and Monocytic Leukemia	1,153	7.1	7.4	6.8	7.7	7.2
Acute Myeloid Leukemia	772	4.3	5.1	4.3	5.6	4.9
Acute Monocytic Leukemia	42	0.3	0.4	0.4	-	0.2
Chronic Myeloid Leukemia	307	2.2	1.7	2.1	1.8	1.8
Other Leukemia	195	1.2	1.6	1.4	1.0	1.3
<b>Ill-Defined &amp; Unspecified Sites</b>	2,459	14.6	14.0	12.9	*19.3	*17.9

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

\* Increase in Ill-Defined & Unspecified rates is due to newly reportable ill-defined cases beginning in 2001.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 4. Age-adjusted Incidence Rates, White Females**

Cancer Site	Total Cases	Rates				
		1998	1999	2000	2001	2002 Prelim.
<b>All Sites</b>	97,040	472.8	463.5	466.1	469.6	455.7
<b>Oral Cavity and Pharynx</b>	1,268	5.9	6.9	5.8	5.9	5.6
Lip	65	0.3	0.3	0.3	0.3	0.3
Tongue	328	1.5	1.7	1.6	1.7	1.5
Salivary Gland	204	1.1	0.9	1.0	1.0	1.0
Floor of Mouth	91	0.5	0.4	0.4	0.4	0.5
Gum and Other Mouth	277	1.2	1.8	1.2	1.2	1.1
Nasopharynx	47	0.2	0.2	0.2	0.2	0.4
Tonsil	104	0.4	0.8	0.4	0.5	0.4
Oropharynx	46	0.2	0.3	0.3	0.2	0.2
Hypopharynx	64	0.3	0.3	0.3	0.3	0.3
<b>Digestive System</b>	18,486	85.7	81.6	81.8	81.4	79.5
Esophagus	500	2.1	2.3	2.0	2.4	2.3
Stomach	1,293	6.9	5.9	5.5	4.9	5.1
Small Intestine	293	1.3	1.3	1.3	1.4	1.6
Colon and Rectum	12,098	56.7	52.6	53.3	53.6	51.3
Colon excluding Rectum	9,127	42.1	38.8	39.9	40.8	38.3
Rectum and Rectosigmoid Junction	2,971	14.6	13.8	13.4	12.8	13.0
Anus, Anal Canal and Anorectum	306	1.3	1.4	1.6	1.7	1.4
Liver and Intrahepatic Bile Duct	608	2.7	2.7	2.7	2.9	2.6
Liver	436	1.7	1.9	1.9	2.3	2.1
Intrahepatic Bile Duct	172	1.1	0.8	0.8	0.7	0.5
Gallbladder	352	1.5	1.7	1.5	1.6	1.4
Pancreas	2,439	10.9	11.0	11.4	9.9	10.4
<b>Respiratory System</b>	12,961	60.7	60.2	60.0	60.6	59.9
Larynx	339	2.0	1.6	1.5	1.7	1.4
Lung and Bronchus	12,358	57.6	57.2	57.2	57.7	57.4
<b>Bones and Joints</b>	177	1.4	0.8	1.0	1.0	0.7
<b>Soft Tissue (Including Heart)</b>	547	2.7	2.5	3.0	2.9	2.8
<b>Skin (Excluding Basal and Squamous)</b>	3,372	15.1	14.8	16.3	19.0	20.4
Melanoma of the Skin	3,117	13.8	13.8	15.1	17.9	19.1
<b>Breast (Invasive)</b>	28,400	144.8	145.1	142.4	139.2	133.7
in situ (not included in All Sites)	6,907	34.2	36.6	35.2	35.4	38.3

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

**Table 4 (continued). Age-adjusted Incidence Rates, White Females**

Cancer Site	Total Cases	Rates				
		1998	1999	2000	2001	2002 Prelim.
<b>Female Genital System</b>	12,463	64.8	63.4	62.2	62.4	57.9
Cervix Uteri	1,754	9.9	10.1	9.1	9.7	8.3
Corpus and Uterus, NOS	6,202	31.1	31.2	30.0	31.0	29.6
Corpus Uteri	5,997	29.9	30.2	29.0	30.1	28.9
Uterus, NOS	205	1.2	1.0	1.0	0.9	0.7
Ovary	3,690	19.8	18.9	19.2	17.6	16.2
Vagina	123	0.5	0.5	0.7	0.7	0.5
Vulva	558	2.8	2.1	2.5	2.6	2.7
<b>Urinary System</b>	4,986	22.0	22.3	23.0	23.3	23.9
Urinary Bladder (including in situ)	2,833	12.3	11.9	13.9	13.1	12.5
Kidney and Renal Pelvis	2,019	9.2	9.8	8.7	9.6	10.7
Ureter	110	0.5	0.5	0.3	0.5	0.7
<b>Eye and Orbit</b>	158	1.1	0.6	0.8	0.9	0.4
<b>Brain and Other Nervous System</b>	1,213	6.6	7.1	6.7	5.9	5.1
Brain	1,101	5.9	6.5	6.1	5.4	4.7
<b>Endocrine System</b>	2,620	11.4	12.3	15.6	16.3	17.3
Thyroid	2,486	10.4	11.8	14.9	15.5	16.7
<b>Lymphomas</b>	4,586	23.7	21.6	22.6	22.1	21.4
Hodgkin Lymphoma	588	3.5	3.2	3.5	3.5	3.7
Non-Hodgkin Lymphoma	3,998	20.2	18.4	19.1	18.5	17.8
<b>Myelomas</b>	993	4.6	4.0	4.5	5.1	4.0
<b>Leukemias</b>	2,031	9.8	10.0	10.1	9.6	9.2
Lymphocytic Leukemia	905	4.0	4.5	4.7	4.3	4.5
Acute Lymphocytic Leukemia	226	1.4	1.4	1.6	1.3	1.2
Chronic Lymphocytic Leukemia	631	2.5	2.9	2.8	2.9	3.0
Myeloid and Monocytic Leukemia	950	4.7	4.6	4.7	4.9	4.0
Acute Myeloid Leukemia	669	3.2	3.3	3.2	3.6	2.9
Acute Monocytic Leukemia	39	0.2	-	0.3	-	0.2
Chronic Myeloid Leukemia	209	1.1	1.1	1.1	1.0	0.7
Other Leukemia	176	1.1	0.9	0.7	0.4	0.8
<b>Ill-Defined &amp; Unspecified Sites</b>	2,779	12.4	10.2	10.2	*14.0	*13.6

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

\* Increase in Ill-Defined & Unspecified rates is due to newly reportable ill-defined cases beginning in 2001.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 5. Age-adjusted Incidence Rates, Black Males**

Cancer Site	Total Cases	Rates				
		1998	1999	2000	2001	2002 Prelim.
<b>All Sites</b>	13,110	724.1	705.9	701.3	726.3	688.8
<b>Oral Cavity and Pharynx</b>	442	27.8	15.8	23.3	19.3	19.0
Lip	-	-	-	-	-	-
Tongue	115	7.3	5.4	5.5	4.8	5.3
Salivary Gland	35	3.5	-	0.9	1.8	1.5
Floor of Mouth	40	2.4	1.2	-	2.9	1.4
Gum and Other Mouth	50	2.0	1.3	3.8	1.9	2.5
Nasopharynx	27	-	-	1.6	1.0	2.1
Tonsil	72	5.1	2.4	2.9	2.7	2.8
Oropharynx	22	1.5	-	2.3	-	1.0
Hypopharynx	59	4.5	2.1	4.2	2.5	1.7
<b>Digestive System</b>	2,642	152.5	150.0	146.9	144.1	147.7
Esophagus	258	17.4	12.5	14.9	15.4	9.7
Stomach	345	19.5	22.5	18.5	20.7	20.5
Small Intestine	60	3.4	3.6	2.6	2.4	3.9
Colon and Rectum	1,371	79.9	76.8	80.7	75.0	80.2
Colon excluding Rectum	1,005	58.3	58.6	58.8	56.0	62.1
Rectum and Rectosigmoid Junction	366	21.6	18.2	21.9	19.1	18.1
Anus, Anal Canal and Anorectum	41	1.8	1.9	1.1	1.7	2.1
Liver and Intrahepatic Bile Duct	221	8.7	9.9	10.4	14.7	10.6
Liver	207	7.1	8.7	10.2	14.1	10.4
Intrahepatic Bile Duct	14	1.6	-	-	-	-
Gallbladder	15	1.6	-	-	-	-
Pancreas	273	15.4	19.9	15.8	11.6	15.0
<b>Respiratory System</b>	2,288	141.1	125.4	123.4	120.9	119.9
Larynx	245	11.0	12.2	15.1	13.6	11.1
Lung and Bronchus	1,995	127.9	111.2	106.9	102.9	107.0
<b>Bones and Joints</b>	20	0.9	-	-	-	1.0
<b>Soft Tissue (Including Heart)</b>	76	1.8	4.3	3.6	3.4	3.3
<b>Skin (Excluding Basal and Squamous)</b>	101	5.2	3.4	2.7	4.6	3.7
Melanoma of the Skin	16	-	-	-	1.3	-

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 5 (continued). Age-adjusted Incidence Rates, Black Males**

Cancer Site	Total Cases	Rates				
		1998	1999	2000	2001	2002 Prelim.
<b>Breast</b>	32	-	2.1	-	2.9	1.7
<b>Male Genital System</b>	5,207	264.2	291.2	289.7	308.0	279.8
Prostate	5,142	261.6	289.6	286.5	304.6	277.9
Testis	46	1.3	1.2	1.3	2.0	1.7
Penis	16	-	-	1.7	1.2	-
<b>Urinary System</b>	696	43.2	38.9	42.7	38.1	34.8
Urinary Bladder (Including in situ)	330	23.5	17.7	24.4	22.1	15.1
Kidney and Renal Pelvis	352	19.1	20.2	17.5	15.6	18.8
Ureter	-	-	-	-	-	-
<b>Eye and Orbit</b>	11	0.9	-	-	-	-
<b>Brain and Other Nervous System</b>	117	6.5	5.5	4.3	5.2	3.2
Brain	107	6.4	5.4	4.1	4.3	2.7
<b>Endocrine System</b>	89	2.1	3.6	6.5	3.3	3.0
Thyroid	65	1.6	2.5	4.2	2.4	2.7
<b>Lymphomas</b>	555	27.4	26.1	19.8	23.6	22.7
Hodgkin Lymphoma	84	3.5	5.2	3.2	2.3	2.2
Non-Hodgkin Lymphoma	471	24.0	20.9	16.6	21.3	20.5
<b>Myelomas</b>	246	15.1	12.4	13.9	14.7	13.5
<b>Leukemias</b>	245	14.6	10.5	8.6	13.8	13.4
Lymphocytic Leukemia	102	5.9	4.4	3.1	4.9	7.8
Acute Lymphocytic Leukemia	34	1.4	1.2	-	0.7	2.4
Chronic Lymphocytic Leukemia	61	3.8	2.7	2.6	4.0	5.3
Myeloid and Monocytic Leukemia	125	6.9	4.8	4.8	8.4	5.4
Acute Myeloid Leukemia	80	3.7	3.0	2.2	5.2	4.8
Acute Monocytic Leukemia	5	-	-	-	-	-
Chronic Myeloid Leukemia	39	2.8	-	2.5	2.8	-
Other Leukemia	18	1.8	1.3	-	-	-
<b>Ill-Defined &amp; Unspecified Sites</b>	343	19.5	15.6	14.9	*23.9	*21.7

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

\* Increase in Ill-Defined & Unspecified rates is due to newly reportable ill-defined cases beginning in 2001.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.



**Table 6. Age-adjusted Incidence Rates, Black Females**

Cancer Site	Total Cases	Rates				
		1998	1999	2000	2001	2002 Prelim.
<b>All Sites</b>	11253	441.7	404.9	410.0	399.0	415.0
<b>Oral Cavity and Pharynx</b>	173	7.9	7.9	4.7	4.2	6.5
Lip	-	-	-	-	-	-
Tongue	42	1.3	2.5	0.9	1.3	1.2
Salivary Gland	27	1.1	-	-	1.0	1.2
Floor of Mouth	13	0.9	-	-	-	-
Gum and Other Mouth	32	2.2	-	1.3	-	1.3
Nasopharynx	10	-	-	-	-	-
Tonsil	17	-	1.0	-	-	-
Oropharynx	13	-	0.9	-	-	-
Hypopharynx	9	-	-	-	-	-
<b>Digestive System</b>	2485	101.5	93.6	93.6	94.5	97.8
Esophagus	100	3.8	3.6	4.8	3.0	3.3
Stomach	252	11.5	8.9	9.7	10.6	8.2
Small Intestine	58	1.3	3.4	-	2.9	2.4
Colon and Rectum	1496	60.2	56.0	55.4	57.3	59.6
Colon excluding Rectum	1167	46.9	44.8	42.1	45.8	45.7
Rectum and Rectosigmoid Junction	329	13.3	11.1	13.2	11.5	13.9
Anus, Anal Canal and Anorectum	27	-	-	0.9	1.1	1.2
Liver and Intrahepatic Bile Duct	82	2.4	3.5	3.8	3.6	2.6
Liver	71	2.0	3.3	2.7	3.4	2.4
Intrahepatic Bile Duct	11	-	-	1.1	-	-
Gallbladder	54	3.9	1.6	2.1	1.9	1.2
Pancreas	356	14.4	14.4	15.3	11.8	16.0
<b>Respiratory System</b>	1464	62.5	53.8	52.3	52.9	55.0
Larynx	63	3.7	2.3	2.0	-	2.8
Lung and Bronchus	1379	58.0	51.1	49.3	51.5	51.6
<b>Bones and Joints</b>	16	0.8	0.8	-	-	-
<b>Soft Tissue (Including Heart)</b>	101	3.1	2.1	4.1	3.5	4.6
<b>Skin (Excluding Basal and Squamous)</b>	49	2.4	1.4	1.3	1.5	1.7
Melanoma of the Skin	23	1.1	-	1.0	-	0.9
<b>Breast (Invasive)</b>	3251	120.8	109.8	123.2	111.0	114.1
in situ (not included in All Sites)	664	22.6	22.9	22.5	24.6	23.5

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 6 (continued). Age-adjusted Incidence Rates, Black Females**

Cancer Site	Total Cases	Rates				
		1998	1999	2000	2001	2002 Prelim.
<b>Female Genital System</b>	1535	61.2	55.9	54.8	51.5	51.6
Cervix Uteri	462	17.8	16.3	17.5	13.2	13.9
Corpus and Uterus, NOS	631	25.9	22.5	20.7	24.2	23.3
Corpus Uteri	572	22.4	20.1	19.4	22.5	21.3
Uterus, NOS	59	3.6	2.4	1.3	1.8	2.0
Ovary	330	14.7	12.7	12.0	10.3	9.9
Vagina	26	-	0.9	1.4	1.5	-
Vulva	60	1.5	2.6	2.3	1.5	3.1
<b>Urinary System</b>	465	18.4	17.5	14.7	17.8	20.6
Urinary Bladder (Including in situ)	207	8.5	7.1	7.4	7.8	11.5
Kidney and Renal Pelvis	240	9.5	9.5	6.7	9.3	8.3
Ureter	-	-	-	-	-	-
<b>Eye and Orbit</b>	-	-	-	-	-	-
<b>Brain and Other Nervous System</b>	112	4.9	3.9	3.2	3.6	4.3
Brain	104	4.2	3.7	3.2	3.6	3.8
<b>Endocrine System</b>	226	4.0	5.2	9.7	9.4	8.7
Thyroid	212	3.3	5.0	9.6	8.7	8.0
<b>Lymphomas</b>	450	17.9	17.8	15.2	13.8	12.7
Hodgkin Lymphoma	76	2.7	2.6	2.7	2.4	1.2
Non-Hodgkin Lymphoma	374	15.2	15.2	12.5	11.4	11.5
<b>Myelomas</b>	285	13.0	10.6	13.1	8.0	10.2
<b>Leukemias</b>	214	8.3	7.0	7.8	7.4	8.0
Lymphocytic Leukemia	82	2.8	2.6	2.9	2.5	3.9
Acute Lymphocytic Leukemia	28	1.1	0.7	-	-	1.3
Chronic Lymphocytic Leukemia	48	1.5	1.3	2.2	1.8	2.6
Myeloid and Monocytic Leukemia	104	4.1	3.9	3.3	3.6	3.5
Acute Myeloid Leukemia	57	2.2	2.0	2.3	1.8	1.7
Acute Monocytic Leukemia	5	-	-	-	-	-
Chronic Myeloid Leukemia	37	1.5	1.1	0.8	1.9	1.3
Other Leukemia	28	1.4	-	1.6	1.3	-
<b>Ill-Defined &amp; Unspecified Sites</b>	424	14.8	17.7	12	*19.2	*19.1

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

\* Increase in Ill-Defined & Unspecified rates is due to newly reportable ill-defined cases beginning in 2001.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 7. Age-adjusted Incidence Rates, Hispanic Males and Females  
1998-2002 Combined**

Cancer Site	Male Rate	Male Cases	Female Rate	Female Cases
<b>All Sites</b>	543.5	6,851	353.8	6,479
<b>Oral Cavity and Pharynx</b>	12.1	184	4.5	78
Lip	0.4	5	-	-
Tongue	4.1	63	1.1	21
Salivary Gland	0.7	11	0.9	15
Floor of Mouth	0.7	10	0.4	5
Gum and Other Mouth	1.7	23	1.0	16
Nasopharynx	0.7	12	0.3	6
Tonsil	1.5	26	0.4	7
Oropharynx	0.8	10	-	-
Hypopharynx	1.4	21	-	-
<b>Digestive System</b>	121.4	1,474	81.5	1,287
Esophagus	7.4	94	2.6	36
Stomach	19.2	252	8.4	136
Small Intestine	1.8	25	1.5	27
Colon and Rectum	63.3	743	45.8	725
Colon excluding Rectum	44.8	507	32.7	512
Rectum and Rectosigmoid Junction	18.5	236	13.1	213
Anus, Anal Canal and Anorectum	0.6	7	1.6	28
Liver and Intrahepatic Bile Duct	12.8	168	5.3	84
Liver	11.4	155	4.2	65
Intrahepatic Bile Duct	1.4	13	1.2	19
Gallbladder	1.6	19	3.3	49
Pancreas	12.2	137	9.7	150
<b>Respiratory System</b>	67.2	802	26.0	413
Larynx	6.3	92	1.0	19
Lung and Bronchus	59.3	676	24.3	381
<b>Bones and Joints</b>	1.1	28	1.2	30
<b>Soft Tissue (Including Heart)</b>	3.3	66	2.6	56
<b>Skin (Excluding Basal and Squamous)</b>	7.7	128	3.9	81
Melanoma of the Skin	4.9	70	3.2	66
<b>Breast (Invasive)</b>	0.4	7	101.5	1,959
in situ (not included in All Sites)	-	-	22.9	468

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

\*\* Non-applicable gender

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 7 (continued). Age-adjusted Incidence Rates, Hispanic Males and Females  
1998-2002 Combined**

Cancer Site	Male Rate	Male Cases	Female Rate	Female Cases
<b>Female Genital System</b>	**	**	50.8	1,019
Cervix Uteri	**	**	15.3	359
Corpus and Uterus, NOS	**	**	20.4	367
Corpus Uteri	**	**	19.4	352
Uterus, NOS	**	**	1.0	15
Ovary	**	**	11.6	234
Vagina	**	**	0.5	10
Vulva	**	**	2.5	37
<b>Male Genital System</b>	205.8	2,432	**	**
Prostate	200.0	2,279	**	**
Testis	3.5	121	**	**
Penis	1.9	29	**	**
<b>Urinary System</b>	46.9	536	17.4	284
Urinary Bladder (Including in situ)	31.6	327	8.8	131
Kidney and Renal Pelvis	14.1	198	8.4	149
Ureter	-	-	-	-
<b>Eye and Orbit</b>	0.5	9	0.4	7
<b>Brain and Other Nervous System</b>	7.0	126	5.4	120
Brain	6.5	114	4.7	106
<b>Endocrine System</b>	4.6	89	13.1	330
Thyroid	3.5	71	12.3	312
<b>Lymphomas</b>	28.9	477	18.5	361
Hodgkin Lymphoma	3.8	94	2.5	66
Non-Hodgkin Lymphoma	25.1	383	15.9	295
<b>Myelomas</b>	8.9	99	6.1	91
<b>Leukemias</b>	13.2	222	9.0	183
Lymphocytic Leukemia	4.8	91	4.2	88
Acute Lymphocytic Leukemia	1.7	53	1.9	53
Chronic Lymphocytic Leukemia	2.7	28	2.1	29
Myeloid and Monocytic Leukemia	6.9	113	4.1	81
Acute Myeloid Leukemia	3.7	68	2.7	56
Acute Monocytic Leukemia	-	-	-	-
Chronic Myeloid Leukemia	2.4	38	0.8	16
Other Leukemia	1.6	18	0.7	14
<b>Ill-Defined &amp; Unspecified Sites</b>	14.4	172	11.9	180

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

\*\* Non-applicable gender.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 8. Comparative Incidence Rates, New Jersey and U.S., 1997-2001  
Males**

<b>Cancer Site</b>	<b>New Jersey 1997-2001</b>			<b>United States 1997-2001</b>		
<b>Population:</b>	All Races Combined	White	Black	All Races Combined	White	Black
<b>All Sites</b>	628.7	625.4	713.0	566.1	558.5	651.1
<b>Colorectal</b>	77.2	77.7	77.4	67.1	66.7	71.0
<b>Lung</b>	90.1	89.0	113.8	90.0	89.1	112.7
<b>Prostate</b>	198.0	189.7	286.0	166.7	158.0	248.2
<b>Melanoma</b>	20.6	23.8	0.9	19.2	21.1	1.3
<b>Non-Hodgkin Lymphoma</b>	25.9	26.4	19.4	22.7	23.1	17.2

Source: NAACCR Age-adjusted rates per 100,000 (U.S. 2000 Standard population)

**Table 9. Comparative Incidence Rates, New Jersey and U.S., 1997-2001  
Females**

<b>Cancer Site</b>	<b>New Jersey 1997-2001</b>			<b>United States 1997-2001</b>		
<b>Population:</b>	All Races Combined	White	Black	All Races Combined	White	Black
<b>All Sites</b>	452.3	463.7	413.3	420.0	425.8	383.5
<b>Colorectal</b>	54.2	54.2	56.7	48.7	48.0	54.0
<b>Lung</b>	55.4	57.1	52.4	54.0	55.5	48.9
<b>Breast (invasive)</b>	138.2	143.0	116.2	132.2	135.1	110.8
<b>Melanoma</b>	12.6	15.0	1.1	12.3	13.9	1.0
<b>Non-Hodgkin Lymphoma</b>	18.5	19.1	13.8	16.1	16.5	11.2

Source: NAACCR Age-adjusted rates per 100,000 (U.S. 2000 Standard population)

**Table 10. Age-adjusted Mortality Rates, Males All Races Combined**

Cancer Site	Total Cases	Rates			
		1998	1999	2000	2001
<b>All Sites</b>	35,861	260.5	258.2	249.1	246.2
<b>Oral Cavity and Pharynx</b>	605	4.2	4.0	3.6	4.3
Lip	6	-	-	-	-
Tongue	156	0.9	1.2	1.0	1.0
Salivary Gland	48	0.3	0.3	0.3	0.4
Floor of Mouth	16	-	-	0.1	-
Gum and Other Mouth	66	0.7	0.4	0.2	0.4
Nasopharynx	63	0.4	0.2	0.5	0.5
Tonsil	51	0.3	0.4	0.1	0.5
Oropharynx	55	0.3	0.4	0.3	0.4
Hypopharynx	31	0.3	0.2	0.2	0.2
<b>Digestive System</b>	9,427	65.6	69.0	66.5	64.0
Esophagus	1,184	8.0	7.9	8.2	7.9
Stomach	1,139	8.8	8.5	7.4	7.4
Small Intestine	80	0.4	0.7	0.5	0.5
Colon and Rectum	3,851	27.2	28.7	28.4	26.3
Colon excluding Rectum	3,244	22.9	24.6	23.5	22.3
Rectum and Rectosigmoid Junction	607	4.2	4.0	4.9	4.1
Anus	18	0.2	-	-	-
Liver and Intrahepatic Bile Duct	1,044	6.9	6.7	7.6	7.4
Liver	863	5.6	5.4	6.1	6.2
Intrahepatic Bile Duct	181	1.3	1.2	1.5	1.2
Gallbladder	85	0.6	0.7	0.4	0.7
Pancreas	1,835	12.3	13.8	12.7	12.5
<b>Respiratory System</b>	10,985	80.7	75.6	73.2	73.6
Larynx	376	2.9	2.7	1.9	2.5
Lung and Bronchus	10,520	77.0	72.2	70.8	70.5
<b>Bones and Joints</b>	71	0.5	0.5	0.4	0.5
<b>Soft Tissue (Including Heart)</b>	239	2.0	1.6	1.5	1.3
<b>Skin (Excluding Basal and Squamous)</b>	776	5.9	5.2	5.1	5.2
Melanoma of the Skin	611	4.6	4.0	4.0	4.1

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 10 (continued). Age-adjusted Mortality Rates, Males All Races Combined**

Cancer Site	Total Cases	Rates			
		1998	1999	2000	2001
<b>Breast</b>	60	0.3	0.4	0.5	0.4
<b>Male Genital System</b>	4,029	34.0	30.9	30.0	30.4
Prostate	3,968	33.7	30.5	29.5	30.0
Testis	33	0.2	0.2	0.2	0.2
Penis	24	-	0.2	0.2	0.1
<b>Urinary System</b>	2,079	15.2	15.7	15.5	14.3
Urinary Bladder	1,195	9.0	9.7	9.3	8.1
Kidney and Renal Pelvis	841	6.1	5.6	5.8	5.9
Ureter	21	-	0.2	0.2	0.2
<b>Eye</b>	8	-	-	-	-
<b>Brain and Other Nervous System</b>	735	5.1	4.4	4.9	4.6
<b>Endocrine System</b>	128	0.6	0.9	1.0	1.0
Thyroid	78	0.4	0.6	0.5	0.7
<b>Lymphomas</b>	1,670	12.7	11.7	11.6	10.5
Hodgkin Lymphoma	90	0.6	0.7	0.6	0.5
Non-Hodgkin Lymphoma	1,580	12.2	11.0	11.0	10.0
<b>Multiple Myeloma</b>	649	4.6	4.1	4.7	5.1
<b>Leukemias</b>	1,435	10.6	11.3	9.9	8.6
Lymphocytic Leukemia	409	3.3	3.5	2.7	2.3
Acute Lymphocytic Leukemia	85	0.7	0.7	0.5	0.5
Chronic Lymphocytic Leukemia	292	2.4	2.6	2.0	1.6
Myeloid and Monocytic Leukemia	597	4.2	4.5	4.0	3.6
Acute Myeloid Leukemia	440	3.0	3.4	3.0	2.6
Acute Monocytic Leukemia	6	-	-	-	-
Chronic Myeloid Leukemia	127	1.1	0.9	0.9	0.7
Other Leukemia	429	3.1	3.4	3.2	2.7
<b>Ill-Defined &amp; Unspecified Sites</b>	2,965	18.2	22.7	20.6	22.3

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 11. Age-adjusted Mortality Rates, Females All Races Combined**

Cancer Site	Total Cases	Rates			
		1998	1999	2000	2001
<b>All Sites</b>	36,587	179.2	178.7	178.0	176.4
<b>Oral Cavity and Pharynx</b>	311	1.6	1.5	1.3	1.6
Lip	-	-	-	-	-
Tongue	89	0.5	0.3	0.4	0.6
Salivary Gland	34	0.2	0.2	0.1	0.1
Floor of Mouth	8	-	-	-	-
Gum and Other Mouth	64	0.3	0.4	0.2	0.3
Nasopharynx	21	-	0.1	-	0.1
Tonsil	22	0.1	0.1	0.1	-
Oropharynx	18	-	-	0.1	0.1
Hypopharynx	7	-	-	-	-
<b>Digestive System</b>	8,733	41.8	42.1	40.5	40.6
Esophagus	394	1.9	2.0	1.9	1.8
Stomach	853	4.6	4.5	3.7	3.5
Small Intestine	55	0.3	0.3	0.3	0.3
Colon and Rectum	4,215	20.4	19.8	19.1	19.6
Colon excluding Rectum	3,679	18.1	17.2	16.4	17.1
Rectum and Rectosigmoid Junction	536	2.4	2.6	2.7	2.5
Anus	24	0.1	0.2	-	0.1
Liver and Intrahepatic Bile Duct	613	2.9	2.8	2.9	3.1
Liver	411	2.0	1.9	1.8	2.2
Intrahepatic Bile Duct	202	0.9	1.0	1.1	0.9
Gallbladder	218	1.1	1.2	1.0	0.9
Pancreas	2,105	9.4	10.1	10.3	10.3
<b>Respiratory System</b>	8,448	42.6	40.6	42.0	41.5
Larynx	121	0.7	0.6	0.5	0.6
Lung and Bronchus	8,282	41.7	39.7	41.3	40.6
<b>Bones and Joints</b>	53	0.2	0.3	0.3	0.3
<b>Soft Tissue (Including Heart)</b>	267	1.4	1.3	1.5	1.3
<b>Skin (Excluding Basal and Squamous)</b>	433	2.3	2.1	1.9	2.1
Melanoma of the Skin	357	1.9	1.8	1.5	1.8
<b>Breast</b>	5,984	30.8	28.8	30.9	28.7

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.



**Table 11 (continued). Age-adjusted Mortality Rates, Females All Races Combined**

Cancer Site	Total Cases	Rates			
		1998	1999	2000	2001
<b>Female Genital System</b>	3,770	18.5	18.2	18.7	19.5
Cervix Uteri	566	2.8	3.2	2.8	3.1
Corpus and Uterus, NOS	1,053	5.4	4.5	5.1	5.5
Corpus Uteri	426	2.4	1.8	2.1	2.1
Uterus, NOS	627	3.1	2.7	3.0	3.4
Ovary	1,936	9.3	9.5	9.6	10.0
Vagina	39	0.2	0.3	0.1	0.2
Vulva	129	0.6	0.5	0.8	0.5
<b>Urinary System</b>	1,173	5.5	5.3	5.6	5.8
Urinary Bladder	582	2.6	2.5	2.6	2.9
Kidney and Renal Pelvis	560	2.7	2.6	2.8	2.8
Ureter	20	0.1	0.1	0.1	-
<b>Eye</b>	11	-	-	-	-
<b>Brain and Other Nervous System</b>	632	3.3	3.8	3.0	3.0
<b>Endocrine System</b>	159	0.8	0.7	0.8	0.8
Thyroid	108	0.4	0.6	0.5	0.6
<b>Lymphomas</b>	1,594	8.2	7.8	7.4	7.3
Hodgkin Lymphoma	91	0.4	0.5	0.6	0.5
Non-Hodgkin Lymphoma	1,503	7.8	7.3	6.8	6.8
<b>Multiple Myeloma</b>	724	3.5	3.3	3.5	3.5
<b>Leukemias</b>	1,211	6.0	6.2	5.5	5.8
Lymphocytic Leukemia	325	1.5	1.8	1.3	1.5
Acute Lymphocytic Leukemia	63	0.4	0.3	0.3	0.3
Chronic Lymphocytic Leukemia	239	0.9	1.3	1.0	1.1
Myeloid and Monocytic Leukemia	510	2.6	2.5	2.5	2.6
Acute Myeloid Leukemia	386	2.0	1.9	1.8	1.9
Acute Monocytic Leukemia	5	-	-	-	-
Chronic Myeloid Leukemia	102	0.6	0.5	0.6	0.5
Other Leukemia	376	1.9	1.9	1.6	1.6
<b>Ill-Defined &amp; Unspecified Sites</b>	3,084	12.5	16.7	15.1	14.7

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 12. Age-adjusted Mortality Rates, White Males**

Cancer Site	Total Cases	Rates			
		1998	1999	2000	2001
<b>All Sites</b>	30,837	255.4	254.1	244.5	242.5
<b>Oral Cavity and Pharynx</b>	450	3.7	3.3	3.0	4.0
Lip	6	-	-	-	-
Tongue	122	0.8	1.0	0.8	1.1
Salivary Gland	40	0.3	0.3	0.3	0.3
Floor of Mouth	11	-	-	-	-
Gum and Other Mouth	55	0.7	0.4	0.2	0.4
Nasopharynx	39	0.2	0.2	0.4	0.4
Tonsil	37	0.3	0.3	0.1	0.4
Oropharynx	35	0.2	0.2	0.2	0.4
Hypopharynx	20	0.2	-	-	0.2
<b>Digestive System</b>	8,024	64.2	66.6	65.1	62.8
Esophagus	994	7.9	7.5	8.2	7.5
Stomach	927	8.3	7.8	7.1	6.7
Small Intestine	66	0.5	0.7	0.4	0.5
Colon and Rectum	3,367	27.0	28.8	27.9	26.3
Colon excluding Rectum	2,833	22.8	25.0	22.7	22.2
Rectum and Rectosigmoid Junction	534	4.2	3.8	5.2	4.1
Anus	14	0.1	-	-	-
Liver and Intrahepatic Bile Duct	829	6.5	6.1	6.9	6.8
Liver	672	5.2	4.9	5.5	5.6
Intrahepatic Bile Duct	157	1.3	1.2	1.5	1.2
Gallbladder	78	0.6	0.8	0.4	0.7
Pancreas	1,578	12.2	13.0	12.7	12.7
<b>Respiratory System</b>	9,441	79.1	75.2	71.8	72.1
Larynx	290	2.7	2.6	1.6	2.1
Lung and Bronchus	9,071	75.7	71.8	69.8	69.4
<b>Bones and Joints</b>	64	0.5	0.6	0.5	0.5
<b>Soft Tissue (Including Heart)</b>	209	1.9	1.7	1.6	1.3
<b>Skin (Excluding Basal and Squamous)</b>	747	6.5	5.9	5.5	5.9
Melanoma of the Skin	602	5.3	4.5	4.5	4.8

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 12 (continued). Age-adjusted Mortality Rates, White Males**

Cancer Site	Total Cases	1998	1999	2000	2001
<b>Breast</b>	52	0.3	0.4	0.4	0.5
<b>Male Genital System</b>	3,281	30.9	28.9	27.1	27.5
Prostate	3,225	30.6	28.4	26.5	27.1
Testis	30	0.2	0.2	0.3	0.2
Penis	22	-	0.2	0.2	0.1
<b>Urinary System</b>	1,898	15.9	15.9	16.1	14.9
Urinary Bladder	1,113	9.5	10.0	9.7	8.6
Kidney and Renal Pelvis	747	6.2	5.5	6.1	6.0
Ureter	20	-	0.2	0.2	-
<b>Eye</b>	8	-	-	-	-
<b>Brain and Other Nervous System</b>	680	5.5	4.7	5.5	5.1
<b>Endocrine System</b>	110	0.6	0.8	0.9	1.1
Thyroid	70	0.4	0.6	0.6	0.7
<b>Lymphomas</b>	1,492	13.0	11.8	12.0	11.0
Hodgkin Lymphoma	76	0.5	0.6	0.7	0.6
Non-Hodgkin Lymphoma	1,416	12.6	11.2	11.3	10.4
<b>Multiple Myeloma</b>	535	4.2	3.9	4.5	4.8
<b>Leukemias</b>	1,278	10.8	11.6	10.2	8.9
Lymphocytic Leukemia	366	3.3	3.6	2.9	2.4
Acute Lymphocytic Leukemia	72	0.7	0.7	0.5	0.5
Chronic Lymphocytic Leukemia	268	2.5	2.7	2.1	1.6
Myeloid and Monocytic Leukemia	526	4.4	4.4	4.0	3.8
Acute Myeloid Leukemia	389	3.2	3.4	3.0	2.7
Acute Monocytic Leukemia	6	-	-	-	-
Chronic Myeloid Leukemia	109	1.2	0.8	0.8	0.8
Other Leukemia	386	3.1	3.6	3.3	2.7
<b>Ill-Defined and Unspecified Sites</b>	2,568	17.9	22.6	20.3	22.2

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 13. Age-adjusted Mortality Rates, White Females**

Cancer Site	Total Cases	Rates			
		1998	1999	2000	2001
<b>All Sites</b>	32,014	179.3	179.5	179.1	178.0
<b>Oral Cavity and Pharynx</b>	259	1.6	1.3	1.3	1.6
Lip	-	-	-	-	-
Tongue	79	0.5	0.3	0.4	0.6
Salivary Gland	33	0.2	0.2	0.2	0.2
Floor of Mouth	5	-	-	-	-
Gum and Other Mouth	57	0.3	0.4	0.2	0.3
Nasopharynx	10	-	-	-	-
Tonsil	15	0.1	-	0.1	-
Oropharynx	16	-	-	0.1	0.1
Hypopharynx	5	-	-	-	-
<b>Digestive System</b>	7,551	41.0	41.4	40.0	39.0
Esophagus	314	1.7	1.8	1.8	1.5
Stomach	687	4.3	3.9	3.5	2.9
Small Intestine	44	0.3	0.3	0.2	0.3
Colon and Rectum	3,720	20.2	19.8	19.1	19.5
Colon excluding Rectum	3,235	17.8	17.2	16.2	17.0
Rectum and Rectosigmoid Junction	485	2.4	2.6	2.9	2.5
Anus	24	0.2	0.2	-	0.1
Liver and Intrahepatic Bile Duct	514	2.9	2.8	2.7	2.7
Liver	342	2.0	1.7	1.8	1.9
Intrahepatic Bile Duct	172	0.9	1.1	1.0	0.8
Gallbladder	185	1.0	1.1	1.0	0.9
Pancreas	1,837	9.4	10.1	10.3	10.1
<b>Respiratory System</b>	7,508	43.2	41.4	43.4	42.9
Larynx	105	0.7	0.6	0.5	0.7
Lung and Bronchus	7,362	42.3	40.5	42.8	41.9
<b>Bones and Joints</b>	45	0.2	0.3	0.3	0.3
<b>Soft Tissue (Including Heart)</b>	228	1.4	1.3	1.5	1.2
<b>Skin (Excluding Basal and Squamous)</b>	417	2.6	2.4	2.0	2.4
Melanoma of the Skin	346	2.2	2.1	1.6	2.1
<b>Breast</b>	5,165	31.0	29.0	30.8	28.7

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 13 (continued). Age-adjusted Mortality Rates, White Females**

Cancer Site	Total Cases	Rates			
		1998	1999	2000	2001
<b>Female Genital System</b>	3,257	18.6	18.0	18.4	20.0
Cervix Uteri	420	2.5	2.6	2.4	3.1
Corpus and Uterus, NOS	899	5.3	4.3	4.8	5.7
Corpus Uteri	381	2.4	1.8	2.0	2.3
Uterus, NOS	518	2.9	2.5	2.8	3.4
Ovary	1,743	9.8	10.0	9.9	10.3
Vagina	34	0.2	0.3	-	0.2
Vulva	119	0.6	0.5	0.8	0.5
<b>Urinary System</b>	1,050	5.3	5.5	5.6	5.9
Urinary Bladder	520	2.4	2.6	2.7	2.8
Kidney and Renal Pelvis	502	2.7	2.8	2.8	3.0
Ureter	18	0.1	-	0.1	-
<b>Eye</b>	11	-	-	-	-
<b>Brain and Other Nervous System</b>	583	3.7	4.1	3.3	3.3
<b>Endocrine System</b>	141	0.9	0.7	0.9	0.8
Thyroid	98	0.4	0.6	0.6	0.6
<b>Lymphomas</b>	1,454	8.5	8.1	7.8	7.7
Hodgkin Lymphoma	85	0.5	0.5	0.6	0.6
Non-Hodgkin Lymphoma	1,369	8.0	7.6	7.2	7.1
<b>Multiple Myeloma</b>	587	3.2	2.9	3.3	3.2
<b>Leukemias</b>	1,091	6.1	6.5	5.6	6.1
Lymphocytic Leukemia	301	1.5	1.9	1.4	1.7
Acute Lymphocytic Leukemia	61	0.5	0.4	0.3	0.4
Chronic Lymphocytic Leukemia	221	0.9	1.4	0.9	1.1
Myeloid and Monocytic Leukemia	453	2.7	2.6	2.5	2.8
Acute Myeloid Leukemia	349	2.1	2.0	1.8	2.1
Acute Monocytic Leukemia	-	-	-	-	-
Chronic Myeloid Leukemia	87	0.5	0.4	0.6	0.5
Other Leukemia	337	1.9	1.9	1.7	1.7
<b>Ill-Defined &amp; Unspecified Sites</b>	2,667	12.2	16.6	14.9	14.6

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 14. Age-adjusted Mortality Rates, Black Males**

Cancer Site	Total Cases	Rates			
		1998	1999	2000	2001
<b>All Sites</b>	4,487	350.4	336.0	346.6	330.8
<b>Oral Cavity and Pharynx</b>	138	9.7	10.5	9.6	7.3
Lip	-	-	-	-	-
Tongue	34	1.9	2.7	3.8	-
Salivary Gland	6	-	-	-	-
Floor of Mouth	-	-	-	-	-
Gum and Other Mouth	11	-	-	-	-
Nasopharynx	16	1.8	-	1.6	-
Tonsil	13	-	-	-	1.2
Oropharynx	18	-	2.0	-	-
Hypopharynx	10	-	-	-	-
<b>Digestive System</b>	1,196	80.8	91.4	90.2	84.6
Esophagus	174	10.4	13.6	11.0	12.8
Stomach	171	13.2	13.7	12.6	13.4
Small Intestine	12	-	-	2.1	-
Colon and Rectum	445	32.3	31.8	37.0	32.0
Colon excluding Rectum	383	26.9	24.1	35.0	29.1
Rectum and Rectosigmoid Junction	62	5.4	7.6	2.0	2.9
Anus	-	-	-	-	-
Liver and Intrahepatic Bile Duct	152	8.8	8.1	9.8	12.4
Liver	137	7.6	7.6	8.9	11.3
Intrahepatic Bile Duct	15	-	-	-	1.0
Gallbladder	-	-	-	-	-
Pancreas	217	14.4	20.2	15.9	12.2
<b>Respiratory System</b>	1,423	112.9	96.6	102.6	102.2
Larynx	77	6.3	4.3	4.8	7.0
Lung and Bronchus	1,338	106.1	91.8	96.9	95.2
<b>Bones and Joints</b>	7	-	-	-	-
<b>Soft Tissue (Including Heart)</b>	28	2.1	1.2	1.2	1.6
<b>Skin (Excluding Basal and Squamous)</b>	23	1.4	-	1.9	-
Melanoma of the Skin	7	-	-	-	-

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 14 (continued). Age-adjusted Mortality Rates, Black Males**

Cancer Site	Total Cases	Rates			
		1998	1999	2000	2001
<b>Breast</b>	7	-	-	-	-
<b>Male Genital System</b>	712	74.8	59.9	70.9	69.8
Prostate	708	74.6	59.5	70.4	69.8
Testis	-	-	-	-	-
Penis	-	-	-	-	-
<b>Urinary System</b>	159	10.2	17.9	11.7	10.9
Urinary Bladder	72	4.7	9.3	6.8	4.8
Kidney and Renal Pelvis	82	5.5	8.4	3.8	5.9
Ureter	-	-	-	-	-
<b>Eye</b>	-	-	-	-	-
<b>Brain and Other Nervous System</b>	41	4.0	2.7	2.3	1.5
<b>Endocrine System</b>	14	-	1.2	1.0	-
Thyroid	6	-	-	-	-
<b>Lymphomas</b>	149	10.0	10.4	10.1	6.8
Hodgkin Lymphoma	14	0.9	1.4	-	-
Non-Hodgkin Lymphoma	135	9.1	9.0	9.8	6.7
<b>Multiple Myeloma</b>	105	9.7	6.2	7.2	8.9
<b>Leukemias</b>	128	9.7	8.8	8.6	7.1
Lymphocytic Leukemia	38	3.2	3.3	1.4	2.0
Acute Lymphocytic Leukemia	10	-	-	-	-
Chronic Lymphocytic Leukemia	22	1.6	2.3	-	1.4
Myeloid and Monocytic Leukemia	57	2.4	5.2	4.7	2.7
Acute Myeloid Leukemia	42	1.5	3.2	3.0	2.4
Acute Monocytic Leukemia	-	-	-	-	-
Chronic Myeloid Leukemia	13	-	1.6	-	-
Other Leukemia	33	4.1	-	2.4	2.4
<b>Ill-Defined &amp; Unspecified Sites</b>	357	23.5	27.3	28.6	28.4

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 15. Age-adjusted Mortality Rates, Black Females**

Cancer Site	Total Cases	Rates			
		1998	1999	2000	2001
<b>All Sites</b>	4,056	198.5	198.7	195.8	190.7
<b>Oral Cavity and Pharynx</b>	47	2.6	3.3	1.7	1.7
Lip	-	-	-	-	-
Tongue	8	-	-	-	-
Salivary Gland	-	-	-	-	-
Floor of Mouth	-	-	-	-	-
Gum and Other Mouth	6	-	-	-	-
Nasopharynx	9	-	-	-	-
Tonsil	7	-	-	-	-
Oropharynx	-	-	-	-	-
Hypopharynx	-	-	-	-	-
<b>Digestive System</b>	1,023	51.0	52.1	46.9	54.4
Esophagus	71	4.4	3.4	2.5	3.6
Stomach	122	5.7	7.8	4.6	6.1
Small Intestine	10	-	-	-	-
Colon and Rectum	454	24.3	22.1	22.0	22.8
Colon excluding Rectum	410	22.2	19.2	20.5	20.2
Rectum and Rectosigmoid Junction	44	2.1	2.9	1.5	2.6
Anus	-	-	-	-	-
Liver and Intrahepatic Bile Duct	72	2.5	3.5	2.9	4.9
Liver	51	1.4	3.4	1.5	3.7
Intrahepatic Bile Duct	21	1.1	-	1.4	1.2
Gallbladder	25	1.2	1.7	-	1.3
Pancreas	245	10.9	12.5	12.7	13.5
<b>Respiratory System</b>	864	45.3	42.3	39.8	39.7
Larynx	16	1.3	-	0.9	-
Lung and Bronchus	845	44.0	41.3	38.8	39.6
<b>Bones and Joints</b>	7	-	-	-	-
<b>Soft Tissue (Including Heart)</b>	32	1.1	0.9	1.8	1.6
<b>Skin (Excluding Basal and Squamous)</b>	13	-	-	-	-
Melanoma of the Skin	9	-	-	-	-
<b>Breast</b>	731	33.8	32.2	37.8	31.5

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.



**Table 15 (continued). Age-adjusted Mortality Rates, Black Females**

Cancer Site	Total Cases	Rates			
		1998	1999	2000	2001
<b>Female Genital System</b>	447	19.0	22.2	23.2	19.5
Cervix Uteri	128	5.7	7.8	5.4	4.3
Corpus and Uterus, NOS	139	6.8	6.3	8.1	6.0
Corpus Uteri	40	2.5	1.4	2.8	1.1
Uterus, NOS	99	4.3	4.9	5.3	4.9
Ovary	161	5.6	7.1	8.8	8.4
Vagina	-	-	-	-	-
Vulva	10	-	-	-	-
<b>Urinary System</b>	112	7.6	4.1	5.8	5.2
Urinary Bladder	57	4.1	1.8	2.5	3.3
Kidney and Renal Pelvis	52	3.2	2.0	3.2	2.0
Ureter	-	-	-	-	-
<b>Eye</b>	-	-	-	-	-
<b>Brain and Other Nervous System</b>	38	1.5	2.2	1.8	1.5
<b>Endocrine System</b>	16	-	1.0	0.8	-
Thyroid	8	-	-	-	-
<b>Lymphomas</b>	114	6.1	5.6	4.9	4.5
Hodgkin Lymphoma	6	-	-	-	-
Non-Hodgkin Lymphoma	108	6.0	5.6	4.3	4.4
<b>Multiple Myeloma</b>	131	6.9	6.2	6.2	7.0
<b>Leukemias</b>	106	6.2	5.1	5.1	4.5
Lymphocytic Leukemia	24	1.4	0.9	1.7	-
Acute Lymphocytic Leukemia	-	-	-	-	-
Chronic Lymphocytic Leukemia	18	1.0	-	1.3	-
Myeloid and Monocytic Leukemia	46	3.1	2.1	2.1	1.6
Acute Myeloid Leukemia	29	2.1	1.2	1.6	-
Acute Monocytic Leukemia	-	-	-	-	-
Chronic Myeloid Leukemia	12	1.0	-	-	-
Other Leukemia	36	1.7	2.0	1.3	2.1
<b>Ill-Defined &amp; Unspecified Sites</b>	375	16.4	20.6	19.0	18.0

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 16. Age-adjusted Mortality Rates, Hispanic Males and Females  
1998-2001 Combined**

Cancer Site	Male Rate	Male Cases	Female Rate	Female Cases
<b>All Sites</b>	144.3	1,258	92.8	1,171
<b>Oral Cavity and Pharynx</b>	2.9	28	1.1	13
Lip	-	-	-	-
Tongue	0.8	9	0.5	6
Salivary Gland	-	-	-	-
Floor of Mouth	-	-	-	-
Gum and Other Mouth	0.7	6	-	-
Nasopharynx	-	-	-	-
Tonsil	-	-	-	-
Oropharynx	-	-	-	-
Hypopharynx	-	-	-	-
<b>Digestive System</b>	44.4	397	28.3	328
Esophagus	4.9	44	0.6	6
Stomach	7.0	70	3.4	45
Small Intestine	-	-	-	-
Colon and Rectum	16.7	134	12.1	143
Colon excluding Rectum	13.5	109	10.4	122
Rectum and Rectosigmoid Junction	3.2	25	1.7	21
Anus	-	-	-	-
Liver and Intrahepatic Bile Duct	6.6	69	3.9	43
Liver	5.4	60	3.2	35
Intrahepatic Bile Duct	1.2	9	0.7	8
Gallbladder	-	-	1.7	18
Pancreas	7.3	64	5.3	59
<b>Respiratory System</b>	37.2	330	11.7	142
Larynx	2.1	22	-	-
Lung and Bronchus	35.0	307	11.4	136
<b>Bones and Joints</b>	-	-	0.2	5
<b>Soft Tissue (Including Heart)</b>	0.6	9	0.6	10
<b>Skin (Excluding Basal and Squamous)</b>	1.2	12	0.5	7
Melanoma of the Skin	1.0	10	0.5	7
<b>Breast</b>	0.3	5	15.5	219

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 16 (continued). Age-adjusted Mortality Rates, Hispanic Males and Females  
1998-2001 Combined**

Cancer Site	Male Rate	Male Cases	Female Rate	Female Cases
<b>Female Genital System</b>	**	**	10.3	140
Cervix Uteri	**	**	2.5	44
Corpus and Uterus, NOS	**	**	2.9	34
Corpus Uteri	**	**	1.1	13
Uterus, NOS	**	**	1.8	21
Ovary	**	**	4.4	57
Vagina	**	**	-	-
Vulva	**	**	-	-
<b>Male Genital System</b>	18.5	115	**	**
Prostate	18.1	109	**	**
Testis	-	-	**	**
Penis	-	-	**	**
<b>Urinary System</b>	6.6	53	2.3	27
Urinary Bladder	3.9	25	1.3	14
Kidney and Renal Pelvis	2.8	28	1.0	13
Ureter	-	-	-	-
<b>Eye</b>	-	-	-	-
<b>Brain and Other Nervous System</b>	1.7	26	1.1	20
<b>Endocrine System</b>	0.5	6	0.6	7
Thyroid	-	-	-	-
<b>Lymphomas</b>	7.9	79	4.5	59
Hodgkin Lymphoma	0.3	5	-	-
Non-Hodgkin Lymphoma	7.6	74	4.4	57
<b>Multiple Myeloma</b>	3.9	25	2.5	27
<b>Leukemias</b>	6.2	72	4.1	59
Lymphocytic Leukemia	1.4	20	0.7	12
Acute Lymphocytic Leukemia	0.7	17	0.3	8
Chronic Lymphocytic Leukemia	-	-	-	-
Myeloid and Monocytic Leukemia	3.7	38	1.6	25
Acute Myeloid Leukemia	2.5	29	1.1	17
Acute Monocytic Leukemia	-	-	-	-
Chronic Myeloid Leukemia	1.0	7	0.5	8
Other Leukemia	1.2	14	1.7	22
<b>Ill-Defined &amp; Unspecified Sites</b>	11.9	97	9.3	108

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard

\*\* Non-applicable gender

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

**Table 17. Comparative Mortality Rates, New Jersey and U.S., 1997-2001  
Males**

<b>Cancer Site</b>	<b>New Jersey 1997-2001</b>			<b>United States 1997-2001</b>		
<b>Population:</b>	All Races Combined	White	Black	All Races Combined	White	Black
<b>All Sites</b>	255.2	250.9	341.3	251.1	245.5	347.3
<b>Lung</b>	73.1	72.1	98.0	77.9	76.6	104.1
<b>Prostate</b>	31.5	28.9	67.3	31.5	28.8	70.4
<b>Colorectal</b>	28.0	27.9	33.7	25.3	24.8	34.3

Source-NAACCR Age-adjusted rates per 100,000 (U.S. 2000 Standard population)

**Table 18. Comparative Mortality Rates, New Jersey and U.S., 1997-2001  
Females**

<b>Cancer Site</b>	<b>New Jersey 1997-2001</b>			<b>United States 1997-2001</b>		
<b>Population:</b>	All Races Combined	White	Black	All Races Combined	White	Black
<b>All Sites</b>	179.7	180.7	198.3	166.7	165.5	196.5
<b>Lung</b>	41.3	42.3	40.9	40.8	41.6	39.9
<b>Breast</b>	30.5	30.5	34.9	27.0	26.4	35.4
<b>Colorectal</b>	19.7	19.5	24.0	17.7	17.1	24.5

Source-NAACCR Age-adjusted rates per 100,000 (U.S. 2000 Standard population)

# Cancer Incidence and Mortality in New Jersey, 1998-2002

**Table 19. Population Denominators**

	1997						1998					
	All Races	All Races	White	White	Black	Black	All Races	All Races	White	White	Black	Black
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
00-04	291,241	278,418	220,857	211,060	51,912	49,550	288,014	275,502	216,765	207,231	51,523	49,113
05-09	305,335	291,166	231,234	220,103	55,824	53,980	308,255	293,705	232,213	220,859	56,729	54,763
10-14	278,141	264,393	211,123	199,987	49,591	47,756	284,481	270,522	215,139	204,138	51,097	49,257
15-19	264,428	248,198	199,032	184,964	48,986	47,711	267,577	250,965	200,911	186,514	49,344	48,027
20-24	241,636	234,097	182,359	173,347	42,808	44,255	241,812	233,415	182,059	172,121	42,854	44,232
25-29	278,306	279,191	212,017	207,683	45,895	49,215	276,266	277,108	208,919	204,468	45,358	49,078
30-34	344,012	350,098	273,418	267,596	51,119	56,523	335,211	341,302	265,316	258,417	50,212	56,169
35-39	362,091	369,846	290,264	291,383	48,976	55,173	363,391	371,013	289,596	290,215	50,016	56,232
40-44	324,306	337,654	264,160	268,700	39,968	47,349	334,545	347,078	271,216	275,070	41,797	48,936
45-49	281,179	297,042	231,222	238,518	33,063	40,967	285,035	300,883	233,688	240,691	33,632	41,630
50-54	241,369	259,163	202,215	212,878	25,870	32,974	247,349	266,183	206,161	217,355	26,890	34,353
55-59	179,335	195,671	148,412	159,118	21,591	27,399	190,559	207,611	158,367	169,421	22,124	28,177
60-64	150,228	168,283	126,453	139,526	17,222	22,067	152,252	170,210	127,184	140,134	17,742	22,833
65-69	140,100	170,794	121,985	146,793	14,163	18,898	136,296	166,219	117,751	141,495	14,136	19,186
70-74	121,441	163,811	108,983	145,615	9,666	14,280	122,443	163,338	109,418	144,441	10,048	14,715
75-79	91,464	139,321	83,419	125,985	6,404	10,914	92,982	140,874	84,484	126,928	6,663	11,265
80-84	54,442	99,111	50,369	90,647	3,163	7,096	56,042	100,887	51,759	92,337	3,320	7,049
85+	34,086	89,411	31,483	82,479	2,116	6,106	35,740	92,353	33,006	84,954	2,191	6,467
Total	3,983,140	4,235,668	3,189,005	3,366,382	568,337	632,213	4,018,250	4,269,168	3,203,952	3,376,789	575,676	641,482

  

	1999						2000					
	All Races	All Races	White	White	Black	Black	All Races	All Races	White	White	Black	Black
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
00-04	287,462	275,114	215,439	205,559	51,197	49,174	288,605	276,181	216,424	206,366	50,951	49,089
05-09	309,684	295,052	232,333	220,962	57,043	54,943	309,796	295,226	231,833	220,620	57,114	54,926
10-14	294,507	280,131	222,127	210,858	53,153	51,437	305,570	290,641	230,531	218,758	55,307	53,648
15-19	269,267	252,487	202,095	187,761	49,142	47,814	273,583	256,582	205,380	191,219	49,750	48,287
20-24	243,493	234,381	182,461	171,854	43,430	44,790	244,381	234,943	182,680	171,456	43,867	45,296
25-29	274,458	274,353	205,803	201,011	44,775	48,643	269,655	268,456	200,765	194,815	43,382	47,621
30-34	325,341	331,258	252,770	249,456	48,809	54,912	318,387	324,409	243,200	242,721	47,933	53,978
35-39	362,946	370,291	287,608	287,859	50,519	56,716	359,431	366,552	281,874	282,796	50,633	56,673
40-44	343,088	354,841	276,591	280,256	43,413	50,334	349,605	360,699	280,278	283,791	44,822	51,509
45-49	291,544	307,297	238,700	245,709	34,346	42,147	299,747	315,483	244,657	251,902	35,312	42,889
50-54	256,150	276,145	212,492	224,316	28,355	35,929	265,731	286,821	219,536	231,585	29,798	37,794
55-59	197,560	215,229	164,332	175,638	22,454	28,751	203,941	222,279	169,174	181,071	23,115	29,400
60-64	154,981	173,309	128,537	141,767	18,376	23,705	156,603	175,164	129,130	142,469	18,666	24,125
65-69	133,493	161,967	114,537	136,884	14,099	19,161	132,276	160,187	112,696	134,421	14,214	19,369
70-74	121,915	161,468	108,283	142,034	10,470	15,057	121,473	159,285	107,306	139,198	10,720	15,379
75-79	94,572	143,041	85,790	128,649	6,799	11,515	95,617	144,477	86,425	129,571	6,989	11,700
80-84	57,365	102,699	52,939	93,898	3,431	7,210	58,859	104,652	54,076	95,400	3,638	7,450
85+	37,495	95,208	34,542	87,341	2,367	6,826	39,504	98,477	36,321	90,128	2,489	7,133
Total	4,055,321	4,304,271	3,217,379	3,391,812	582,178	649,064	4,092,764	4,340,514	3,232,286	3,408,287	588,700	656,266

  

	2001						2002					
	All Races	All Races	White	White	Black	Black	All Races	All Races	White	White	Black	Black
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
00-04	287,518	275,710	213,749	204,064	52,017	50,591	287,518	275,710	213,749	204,064	52,017	50,591
05-09	306,700	292,671	228,978	218,298	56,324	53,878	306,700	292,671	228,978	218,298	56,324	53,878
10-14	312,540	297,615	235,220	223,223	56,781	55,205	312,540	297,615	235,220	223,223	56,781	55,205
15-19	282,297	265,958	212,412	198,651	50,774	49,370	282,297	265,958	212,412	198,651	50,774	49,370
20-24	244,899	233,820	182,620	170,683	44,813	45,406	244,899	233,820	182,620	170,683	44,813	45,406
25-29	261,887	258,472	194,364	186,191	42,324	46,020	261,887	258,472	194,364	186,191	42,324	46,020
30-34	315,917	321,263	239,128	237,863	47,958	53,887	315,917	321,263	239,128	237,863	47,958	53,887
35-39	357,935	365,440	278,770	279,307	50,910	57,598	357,935	365,440	278,770	279,307	50,910	57,598
40-44	357,074	367,422	285,213	288,158	46,389	52,771	357,074	367,422	285,213	288,158	46,389	52,771
45-49	310,536	325,499	252,837	259,026	36,676	44,207	310,536	325,499	252,837	259,026	36,676	44,207
50-54	272,054	293,416	224,046	235,616	30,714	39,331	272,054	293,416	224,046	235,616	30,714	39,331
55-59	213,869	233,438	177,646	190,514	23,713	30,105	213,869	233,438	177,646	190,514	23,713	30,105
60-64	159,663	179,249	131,327	145,129	19,008	24,821	159,663	179,249	131,327	145,129	19,008	24,821
65-69	130,937	158,421	110,360	131,394	14,509	20,132	130,937	158,421	110,360	131,394	14,509	20,132
70-74	120,663	156,783	106,240	136,325	10,710	15,434	120,663	156,783	106,240	136,325	10,710	15,434
75-79	95,278	143,230	85,612	127,736	7,251	12,011	95,278	143,230	85,612	127,736	7,251	12,011
80-84	61,434	107,972	56,304	98,213	3,810	7,761	61,434	107,972	56,304	98,213	3,810	7,761
85+	41,919	101,620	38,527	93,000	2,568	7,216	41,919	101,620	38,527	93,000	2,568	7,216
Total	4,133,120	4,377,999	3,253,353	3,423,391	597,249	665,744	4,133,120	4,377,999	3,253,353	3,423,391	597,249	665,744

Source: The National Cancer Institute's SEER Program.

***Cancer Incidence and Mortality in New Jersey, 1998-2002***

**Table 19. Population Denominators**  
**Hispanic Population, 1998-2002**

	Male Total	Male 1998	Male 1999	Male 2000	Male 2001	Male 2002	Female Total	Female 1998	Female 1999	Female 2000	Female 2001	Female 2002
00-04	256,296	48,331	49,705	50,904	53,678	53,678	245,052	46,203	47,523	48,766	51,280	51,280
05-09	246,661	46,356	48,253	50,028	51,012	51,012	236,017	44,584	46,220	47,663	48,775	48,775
10-14	229,197	41,481	43,686	46,474	48,778	48,778	220,357	39,765	42,036	44,856	46,850	46,850
15-19	238,822	46,469	47,418	48,445	48,245	48,245	214,562	41,267	42,145	43,376	43,887	43,887
20-24	274,403	51,956	54,339	56,400	55,854	55,854	233,181	45,127	46,500	47,454	47,050	47,050
25-29	282,317	52,414	54,762	57,201	58,970	58,970	247,123	46,897	48,513	50,019	50,847	50,847
30-34	284,950	55,613	55,617	56,012	58,854	58,854	261,575	50,367	50,979	51,915	54,157	54,157
35-39	265,508	49,118	51,158	52,958	56,137	56,137	253,416	46,976	48,757	50,727	53,478	53,478
40-44	209,323	37,244	39,458	42,083	45,269	45,269	211,606	38,439	40,182	42,491	45,247	45,247
45-49	157,612	28,506	29,679	31,461	33,983	33,983	165,646	30,339	31,500	33,173	35,317	35,317
50-54	122,781	22,329	23,548	24,854	26,025	26,025	134,371	24,712	25,761	27,214	28,342	28,342
55-59	89,865	16,702	17,164	17,927	19,036	19,036	101,511	18,664	19,369	20,174	21,652	21,652
60-64	68,963	12,772	13,318	13,871	14,501	14,501	78,489	14,498	15,099	15,810	16,541	16,541
65-69	47,748	8,999	9,186	9,555	10,004	10,004	60,194	11,206	11,693	12,063	12,616	12,616
70-74	33,284	6,004	6,365	6,615	7,150	7,150	44,797	8,293	8,606	8,934	9,482	9,482
75-79	19,090	3,329	3,531	3,806	4,212	4,212	30,141	5,467	5,710	6,026	6,469	6,469
80-84	10,027	1,817	1,886	1,972	2,176	2,176	18,901	3,508	3,545	3,692	4,078	4,078
85+	7,060	1,185	1,242	1,389	1,622	1,622	16,157	2,856	2,993	3,196	3,556	3,556
Total	2,843,907	530,625	550,315	571,955	595,506	595,506	2,773,096	519,168	537,131	557,549	579,624	579,624

Source: The National Cancer Institute's SEER Program.

**Table 20.**

**Age Distribution (%) of Incidence Cases in New Jersey, 1998-2002  
All Races, Both Sexes**

Site	0-19	20-34	35-44	45-54	55-64	65-74	75-84	85+	All Ages	Cases
All Sites	0.9%	2.3%	5.6%	12.2%	19.7%	27.6%	24.1%	7.6%	100%	229,728
Oral Cavity and Pharynx	0.6%	2.3%	8.1%	19.5%	24.1%	22.3%	17.3%	5.9%	100%	4,428
Esophagus	0.0%	0.2%	2.7%	12.6%	21.3%	31.7%	23.2%	8.2%	100%	2,263
Stomach	0.1%	1.4%	4.4%	8.6%	16.7%	27.2%	28.7%	13.0%	100%	4,236
Colon and Rectum	0.0%	0.8%	3.0%	8.6%	15.9%	27.5%	31.5%	12.6%	100%	27,695
Male	0.0%	0.8%	3.1%	9.4%	18.6%	29.9%	29.3%	8.9%	100%	13,768
Female	0.0%	0.7%	2.9%	7.8%	13.3%	25.2%	33.7%	16.3%	100%	13,927
Colon	0.0%	0.7%	2.5%	7.6%	14.7%	27.4%	33.2%	13.9%	100%	20,091
Rectum	0.0%	0.8%	4.3%	11.3%	19.2%	28.1%	27.1%	9.3%	100%	7,604
Liver & Intrahepatic bile duct	1.1%	1.3%	3.7%	14.6%	19.1%	26.7%	24.6%	9.0%	100%	2,329
Pancreas	0.0%	0.4%	2.4%	8.2%	17.2%	27.4%	31.7%	12.7%	100%	5,375
Lung and Bronchus	0.0%	0.2%	2.3%	8.7%	20.5%	32.8%	28.6%	6.8%	100%	30,221
Male	0.0%	0.2%	2.0%	8.5%	21.3%	34.3%	27.8%	5.9%	100%	16,301
Female	0.0%	0.2%	2.6%	8.9%	19.7%	31.1%	29.5%	7.9%	100%	13,920
Melanoma of the Skin	0.8%	6.5%	12.0%	16.8%	18.2%	22.0%	17.9%	6.0%	100%	7,354
Breast (Female)	0.0%	1.9%	11.1%	21.2%	21.0%	21.2%	17.7%	6.0%	100%	32,806
Cervix Uteri	0.2%	13.8%	23.7%	23.6%	14.9%	11.9%	8.8%	3.2%	100%	2,328
Corpus and Uterus, NOS	0.0%	0.8%	5.2%	16.8%	27.3%	26.7%	18.6%	4.8%	100%	7,011
Ovary	1.1%	3.5%	9.5%	18.5%	21.0%	20.4%	18.8%	7.3%	100%	4,182
Prostate	0.0%	0.0%	0.5%	7.4%	25.4%	38.7%	23.9%	4.2%	100%	37,746
Testis	5.5%	42.7%	33.2%	13.4%	2.8%	1.1%	1.0%	0.3%	100%	1,198
Urinary Bladder	0.1%	0.6%	2.2%	7.6%	16.7%	30.6%	31.7%	10.6%	100%	11,326
Kidney and Renal Pelvis	1.6%	1.2%	5.7%	14.0%	21.1%	28.8%	22.4%	5.2%	100%	5,934
Brain & Nervous System	12.3%	7.9%	9.2%	15.1%	15.3%	20.3%	15.9%	3.9%	100%	2,993
Thyroid	1.7%	18.0%	23.7%	22.0%	15.2%	11.4%	6.9%	1.2%	100%	3,885
Hodgkin Lymphoma	11.8%	32.4%	17.4%	12.8%	9.6%	8.1%	6.4%	1.5%	100%	1,402
Non-Hodgkin Lymphoma	1.7%	4.3%	8.0%	13.3%	16.8%	23.5%	24.4%	8.1%	100%	9,418
Myelomas	0.0%	0.6%	3.0%	10.7%	18.1%	29.1%	27.9%	10.6%	100%	2,654
Leukemia	9.4%	4.1%	5.8%	9.8%	13.8%	21.9%	25.3%	10.0%	100%	5,346
Acute Lymphocytic	57.7%	9.5%	5.0%	6.0%	6.0%	7.1%	6.3%	2.4%	100%	620
Chronic Lymphocytic	0.1%	0.3%	2.2%	8.7%	17.8%	27.3%	31.1%	12.5%	100%	1,665
Acute Myeloid	6.4%	5.8%	7.0%	10.3%	13.5%	22.5%	25.9%	8.6%	100%	1,636
Chronic Myeloid	1.3%	5.7%	12.1%	13.9%	12.8%	23.0%	23.1%	8.1%	100%	627
Other Leukemia	3.7%	3.0%	3.5%	6.9%	9.5%	20.3%	32.1%	21.0%	100%	433

**Table 21.**

**Median Age of Cancer Patients at Diagnosis, New Jersey 1998-2002  
By Primary Cancer Site, Race and Sex**

Site	All Races			Whites			Blacks		
	Total	Male	Female	Total	Male	Female	Total	Male	Female
All Sites	68	69	68	69	69	69	64	65	63
Oral Cavity and Pharynx	63	61	67	64	62	69	57	57	59
Esophagus	69	68	72	70	68	73	65	66	64
Stomach	72	70	75	73	71	76	67	66	70
Colon and Rectum	73	71	75	74	72	75	67	65	68
Colon	74	72	75	74	73	76	67	66	69
Rectum	70	69	72	71	69	73	65	63	68
Liver & Intrahepatic bile duct	69	66	73	71	68	75	59	56	68
Pancreas	73	70	75	73	71	76	69	66	72
Lung and Bronchus	70	70	71	71	71	71	66	66	66
Melanoma of the Skin	62	64	59	62	64	59	61	55	69
Breast	62	67	62	63	68	63	58	64	58
Cervix Uteri	*	*	50	*	*	49	*	*	50
Corpus and Uterus, NOS	*	*	64	*	*	65	*	*	65
Ovary	*	*	63	*	*	64	*	*	59
Prostate	*	69	*	*	70	*	*	66	*
Testis	*	35	*	*	35	*	*	34	*
Urinary Bladder	72	72	74	73	72	74	70	69	72
Kidney and Renal Pelvis	67	65	69	67	66	70	62	62	59
Brain & Nervous System	58	57	60	60	58	61	50	48	53
Thyroid	47	52	46	47	53	46	49	53	49
Lymphoma	65	62	68	67	65	69	50	48	54
Hodgkin Lymphoma	38	39	36	38	39	36	39	39	39
Non-Hodgkin Lymphoma	68	65	70	69	67	71	53	49	57
Myeloma	71	69	72	72	71	74	67	66	67
Leukemia	68	67	70	70	69	71	58	58	59
Acute Lymphocytic	14	16	13	15	16	14	14	16	13
Chronic Lymphocytic	72	71	74	73	72	75	68	67	70
Acute Myeloid	68	68	69	70	70	70	56	57	51
Chronic Myeloid	67	67	67	69	69	69	54	54	54
Other Leukemia	75	74	77	77	75	78	61	54	72

\* Non-applicable gender.